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ABSTRACT 
 
 In an effort to search for potential therapeutic agents for cocaine addiction, a novel class 
of compounds was synthesized and evaluated for in vitro dopamine and serotonin transporter 
affinities. These unique 3β-aryl-3α-arylmethoxytropane analogues incorporated the structure of 
dopamine selective 2-substituted-3-phenyltropanes and the design of serotonin selective 
meperidine derivatives. In general, the 3β-aryl-3α-arylmethoxytropane analogues exhibited 
greater potency for the serotonin transporter than the dopamine transporter. The most potent 
compounds of this series were 3β-phenyl-3α−(3″, 4″-dichlorophenyl)methoxy-8–azabicyclo 
[3.2.1]nortropane (Ki = 0.06 nM) and 3β-(4′-chlorophenyl)-3α−(4″-chlorophenyl)methoxy-8–
azabicyclo[3.2.1]nortropane (Ki = 0.09 nM) at the serotonin transporter and their binding 
affinities were equipotent with paroxetine and fluoxetine (Prozac). 
 A series of 8-azabicyclo[3.2.1]oct-2-ene derivatives were synthesized from 3-tropinone 
based on the structure of triple re-uptake inhibitor, DOV 216,303. The compounds were designed 
as potential triple re-uptake inhibitors which could exhibit equipotent affinities at the monoamine 
transporters for dopamine, serotonin and norepinephrine. 
 A short and efficient synthetic methodology was developed for the synthesis of unique 
compounds which could exhibit potency for both the dopamine and serotonin transporters. The 
3β-aryl-3α-(4′, 4″-disubstituteddiphenylmethoxy)tropane analogues were designed as hybrid 
structures of the dopamine transporter selective benztropines and the serotonin transporter 
selective meperidine derivatives.  
Key Words: tropane, cocaine, dopamine, serotonin, norepinephrine, tropenes. 
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INTRODUCTION 
 
1.1 Structure of Cocaine and Its Abuse Potential 
Cocaine is the most powerful central nervous system stimulant found in nature. (-)-
Cocaine (1a) is a plant alkaloid and is extracted from the leaf of the Erythroxylon coca bush 
which grows primarily in Peru and Bolivia.1 Albert Niemann, a German chemist, was the first to 
isolate this alkaloid from the coca plant in 1860.2 Sigmund Freud was one of the prime 
investigators who studied the effects of cocaine and proposed its clinical use as a local anesthetic 
in eye surgery.3 Its powerful vasoconstrictant properties have been utilized in nose or throat 
surgery where control of bleeding was desired.4 However it was soon realized that the toxic 
effects of this drug were far more severe than its benefit as a medication.5,6 Instances of 
addiction, psychotic behavior, convulsions and even death have been reported. Cocaine use is 
associated with euphoric effects or “high”, consisting of hyper stimulation, reduced fatigue and 
mental alertness for a short period of time. Consequently, it has now become one of the most 
abused drugs in the country. 
Cocaine is one of the eight possible isomeric forms (1a-1h) of the chemical entity methyl 
3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octan-2-carboxylate.7 The potency of R-Cocaine 
(1a) was found to be 60-670 times greater than its isomers.8 There are two main forms of 
cocaine-the hydrochloride salt and the freebase (“Crack”). Cocaine sold as the hydrochloride salt 
is typically snorted, swallowed, or dissolved in water and injected intravenously. The onset of 
the effects of cocaine relies on the mode of its intake. For example, it takes up to 30 minutes to 
feel the effects if snorted but only 1-2 minutes if taken by intravenous injection.  
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The most immediate and intense “high” is produced by smoking the freebase “Crack”.9 Crack is 
available as a rock crystal and is heated and the vapors inhaled. The term “Crack” refers to the 
crackling sound heard when it is heated. It is the most dangerous form of the drug as it is cheap, 
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easy to intake and its effects are rapid and intense.10, 11 Intake of any form of cocaine will result 
in constriction of blood vessels, dilation of pupils and increase in body temperature, heart rate 
and blood pressure. High doses can result in heart attack, strokes, seizures, full blown paranoid 
psychosis, auditory hallucinations or even sudden death.12 A recent survey in the United States 
indicated that 34.2 million Americans aged 12 and over reported lifetime use of cocaine, and 7.8 
million reported using crack.13 There were an estimated 1 million new users of cocaine in 2005, 
approximating to 2,400 per day. In addition the spread of HIV has been linked to drug abusers 
who used/shared injections. When cocaine and alcohol are consumed together, human liver 
manufactures a third substance, cocaethylene, which intensifies cocaine’s euphoric effects and 
increases the risk of sudden death.14 Cocaine addiction is a chronic relapsing disease and the 
withdrawal symptoms are associated with serious depression.15-20 
 Aside from the physical effects suffered by the individual, our society bears the burden of 
cocaine abuse because of decreased productivity, increased premature deaths, disruption of 
families and medical costs associated with emergency room care, as well as treatment and 
prevention programs.21 The health, crime, and other problems created by drug abuse cost society 
nearly half as much money as spent on defense by the Department of Defense.22, 23 While this 
underscores the magnitude of the problem, the amount of human suffering is incalculable.  
In light of all the detrimental effects associated with cocaine abuse, the need for a 
therapeutic agent is immediate and necessary. In this regard, a lot of research has focused on the 
development of a cocaine addiction medication, but at present there are no suitable medications 
for the complete treatment of cocaine abuse.24 The aim has been to design a drug that potentially 
attenuates cocaine intake and yet does not simply substitute one addictive drug for another. This 
substitution therapy has been widely accepted as a feasible strategy for treatment of other drug 
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addictions. For example, methadone has been an effective medication in the treatment of heroin 
abuse25-27 and nicotine replacement has been useful for smoking cessation.28 
 
 
1.2 Cocaine and the Dopamine Transporter 
 The complex molecular mechanisms associated with the action of cocaine that result in 
various physiological and behavioral effects are under intensive investigation. Although several 
binding sites for cocaine have been identified in the brain, the exact mechanisms of interaction 
with these sites are still not fully understood. Cocaine has affinity for several sites in the central 
nervous system. It can inhibit the reuptake of dopamine (2), serotonin (3) and norepinephrine 
(4)29-31 as well as exert effects on the cholinergic muscarinic32 and σ receptors and sodium ion 
channels.33 Any one or a combination of these could result in effects related to the abuse of 
cocaine. Although cocaine has a relatively low affinity for most neurotransmitter receptor sites, it 
has micromolar affinity for  σ receptors and the effects of this interaction may be involved in the 
psychotomimetic effects of the drug.33 The cardiovascular effects like increased heart rate and 
blood pressure are believed to be mediated by the inhibition of norepinephrine uptake.34    
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The reinforcing properties of cocaine are usually predicted by cocaine self administration 
in animals and humans as well as by other behavioral techniques.35 Mechanisms of 
reinforcement have been explored at the neurochemical and neuroanatomical levels. Numerous 
studies over the past several years have suggested that the binding site which mediates cocaine 
self-administration or the reinforcing effects of cocaine is associated with the dopamine 
transporter (DAT).36, 37 It has been established that the mesolimbic dopaminergic neurons in the 
midbrain are mainly responsible for mechanisms associated with reward-related behavior. This 
midbrain dopaminergic projection originates in the ventral tegmental area and projects to 
structures associated with the limbic system, most prominently the nucleus accumbens.38 The 
dopamine transporter  is a protein located on presynaptic nerve terminals that plays a major role 
in the uptake of synaptic dopamine. The cDNA for dopamine transporter  has been cloned from 
rat,39-41 mouse,42, 43 bovine44 and human brain.45 Elucidation of the primary structure of the 
dopamine transporter has revealed that it is a 619-amino acid protein and contains 12 putative 
transmembrane domains.40 It is a member of the large family of sodium dependent transporters. 
Other members of this family include transporters for norepinephrine, serotonin, GABA (γ-
aminobutyric acid), proline, glycine, betaine and creatine.46 Although the dopamine transporter  
has been cloned and expressed, its 3D structure is still unknown. However, site-directed 
mutagenesis studies have revealed that aspartate and serine residues lying within the first and 
seventh hydrophobic putative regions are important for cocaine recognition and dopamine 
uptake.47 It has been contemplated that the carboxyl group of the aspartic acid residue 79 
engages in an ionic interaction either with the nitrogen of cocaine or with the amino group of 
dopamine in binding to the transporter.48  
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1.3 The Dopamine Hypothesis 
 The process of neurotransmission requires synthesis and storage of the neurotransmitter, 
followed by its release and interaction with specific pre- and post-synaptic receptors. 
Termination of the signal results in degradation of the neurotransmitter, its diffusion out of the 
synapse and/or removal from the synapse by one of the sodium-dependent neurotransmitter 
transporters. The importance of each of these processes for dopamine transmission has been 
established.49-51 The predominant theory which tries to explain the reinforcing properties of 
cocaine is the ‘dopamine hypothesis’. It does not associate cocaine addiction with the direct 
binding of cocaine with the dopamine transporter itself but rather with the accumulation of 
dopamine in the synapse and its action at one or more of the D1-D5 receptors.52-54 In normal 
neural stimulation (food, sex, etc.), the presynaptic neuron receives a chemical impulse which 
travels along the axon promoting the release of dopamine.55 The dopamine diffuses into the 
synaptic cleft and interacts with the receptors of the postsynaptic neurons. This interaction results 
in a biochemical reaction which sends another chemical impulse down the axons of the 
postsynaptic neuron signaling satisfaction or reward. Dopamine is released from the receptors 
into the synapse. After its release, the concentration is reduced rapidly due to the presence of 
uptake sites on the plasma membrane of the presynaptic dopaminergic nerve endings. The 
dopamine transporter protein controls the extra cellular dopamine levels by transporting it back 
into the presynaptic neuron where it is recycled for later use. Therefore, the dopamine transporter 
has a fundamental role in the regulation of pre- and postsynaptic dopaminergic transmission. 
 Cocaine is considered to be a classic uptake blocker: it inhibits dopamine uptake after 
normal neuronal activity by binding to the dopamine transporter (Figure 1).55, 56 This leads to an 
 7
 
Figure 1. Dopamine Hypothesis. During normal communication between nerve cells, or neurons, the transmitting 
neuron releases neurotransmitter molecules that stimulate the receiving neuron by binding to receptor molecules on 
its surface. After this communication has occurred, transporter molecules collect the released neurotransmitters and 
transport them back into the transmitting neuron for later release. When cocaine is present, the drug blocks the 
transporter, preventing neurotransmitter reuptake so that the neurotransmitters continue to stimulate the receiving 
neuron.55 
 
 
 
increased concentration of dopamine and it enables the postsynaptic neurons to produce an 
enhanced signal. This enhanced signal results in the euphoric effects of cocaine. But use of 
cocaine over a period of time causes desensitization of the postsynaptic neurons. In order to 
maintain equilibrium, the system reduces the number of receptors present and the remaining 
receptors also become less sensitive to dopamine levels. Meanwhile, the dopamine transporter 
proteins increase in number. The increased number helps to remove excess dopamine from the 
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synapse and mitigates over stimulation. Therefore use of cocaine over a period of time will 
lessen the extent of the initial ‘high’ felt by the user. This will lead the user to administer higher 
doses more frequently to achieve the same level of euphoria and stimulation which ultimately 
leads to a chronic addiction. 
 
 
1.4 Heterogeneity of Dopamine Transporter Binding 
 Numerous radio-labeled ligands have been used to identify and study distinct binding 
sites at the dopamine transporter. The two most extensively characterized molecules are 
[3H]WIN 35,428 (5) and [3H]GBR 12909 (6).57-59  
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 [3H]Cocaine was initially found to bind saturably to a single site in mouse brain 
preparations.60 Later reports showed that [3H]cocaine and other high affinity congeners like 
[3H]WIN 35,428 saturate the dopamine transporter in a biphasic manner characteristic of binding 
to high- and low-affinity components or sites.61-67 The two binding sites might mark discrete 
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transporter molecules, conformational states, or separate binding sites on the same protein. On 
the other hand, dopamine transporter inhibitors [3H]mazindol and [3H]GBR 12909 saturate sites 
on the transporter in a monophasic manner indicative of a single binding site.68 The significance 
of this heterogeneity for behavior related to cocaine abuse is still not very clear. However, 
several studies suggest that the discriminative-stimulus effects of cocaine are mediated mainly by 
the high-affinity component. The further estimation of the contributions of high- and low-affinity 
binding components to cocaine related effects will require development of novel selective 
ligands and advances in their isolation and discriminative study.  
 
 
1.5 Challenges to the Dopamine Hypothesis 
 Significant studies supported the idea of the dopamine transporter as a primary mediator 
of the reinforcing action of cocaine. However, there were numerous reports which noted that 
under chronic cocaine-taking conditions, the dopaminergic system was not the only system 
responsible for craving and dependence, but other neural systems were involved as well.69-72 This 
was suggested mainly from studies conducted on dopamine transporter knock-out mice. Cloning 
and expression of rat cDNA was achieved nearly a decade ago and subsequent homologous 
recombination in which the dopamine transporter gene was disrupted, resulted in the first 
dopamine transporter knock-out (DAT KO) mice.46 These genetically altered mice were found to 
be profoundly hyperactive, conforming with the hypothesis that excessive extracellular 
dopamine increases locomotor behavior. Nevertheless, tests of locomotor activity cannot predict 
abuse-related effects of the drug reliably. A more convincing assessment of such effects comes 
from self-administration procedures, in which the drug serves as a reinforcer of behavioral 
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activity that trigger rapid intravenous infusions of the drug.73 Cocaine was self-administered in 
DAT KO mice despite their already elevated levels of extracellular dopamine. This behavior is in 
direct contradiction of the dopamine hypothesis and this suggests that increase in dopamine 
concentrations is not the only mechanism involved in the reinforcing effects of cocaine. 
Therefore, the role of the serotonin transporter was advocated for mediating these effects.74 
Serotonin knock-out mice were studied and results showed that these mice exhibited the 
rewarding effects of cocaine too. This depicted that increased levels of extracellular serotonin 
also play a role in the actions of cocaine. These studies show that although no single monoamine 
transporter is absolutely necessary for cocaine reward in knock-out mice, several possible roles 
for these neurotransporters in wild type mice remain. Lifelong deletions of dopamine, serotonin 
and the norepinephrine transporters or their combinations, each specifically change the 
rewarding effects of blocking the remaining transporters. It can be concluded from these findings 
that cocaine works as a “dirty drug” that produces reward through simultaneous action at more 
than one transporter site.75 Therefore, strategies for developing drugs acting at both dopamine 
and serotonin brain systems might provide better insights for treating cocaine abuse and its 
reward reinforcement rather than focusing on synthesizing dopamine transporter selective 
ligands exclusively. 
 
 
1.6 Medication Development for Cocaine Abuse  
 A large number of compounds have been synthesized and analyzed as potential 
pharmacotherapeutics for treating cocaine addiction. Most of the compounds are small molecules 
which should act as cocaine antagonists and inhibit cocaine recognition at transporter sites while 
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allowing the neurotransporters to maintain all or most of their normal functions. However, 
despite improved understanding of neural mechanisms underlying the addiction of cocaine, no 
suitable compound has been discovered that can act as a true cocaine antagonist and therefore be 
used as a medication for treating cocaine abuse.76,77 Nevertheless, there are some 
pharmacotherapeutic agents that have been developed from an immunological standpoint. These 
drugs can enable the body to produce cocaine antibodies which bind to cocaine and degrade it. 
The three major classes of pharmacotherapeutics currently available for treating cocaine abuse 
are: drugs that treat coexisting psychiatric disorders (methylphenidate, desipramine, etc.), drugs 
that produce an aversion reaction when taken with cocaine (phenelzine) and drugs that treat 
cocaine craving (L-dopa, tryptophan, carbmazepine, etc.).78, 79 Other pharmacotherapeutic agents 
which have been explored also include excitatory amino acid receptor antagonists,80, 81 5-HT3 
receptor antagonists,82, 83 dopamine receptor agonists/antagonists,84-88 sigma receptor 
antagonists89, 90 and kappa,91 delta opioid receptor ligands.92, 93 
 A pharamacophore model (Fig. 2) for the cocaine binding site was proposed by Carroll et 
al. This was based on structure-activity relationship (SAR) data of a variety of compounds and 
preliminary molecular modeling studies.30  
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Figure 2. Schematic representation of putative interaction of cocaine with its receptor sites. 
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The three main sites of interaction envisaged from these studies were: the hydrogen bond or 
electrostatic site to interact with the nitrogen atom of cocaine, hydrophobic pocket to 
accommodate the benzoyl group and the hydrogen bond interaction with the ester moiety. 
However, it was found that the 2β−carbomethoxy ester is not required for potent binding.94, 95 It 
was also established that the configuration of cocaine and its analogues is fundamental for 
binding with high affinity. Moreover, the tropane ring can be replaced by a piperidine ring 
without significant loss of the binding potency.96  
 A variety of compounds have been evaluated as dopamine uptake inhibitors over the past 
several years. Five broad categories based on their structure are: 
1.) 3-Phenyl tropane analogues (7)                                      2.) GBR related compounds (6) 
3.) Benztropine analogues (8)                                              4.) Methylphenidates (9) 
5.) Mazindol analogues (10) 
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 Although almost all of the above analogues have high affinity for the neurotransporters, 
animal studies have demonstrated that they are not self administered. Many of these compounds 
have been explored as tools for understanding the underlying neural mechanisms for the 
reinforcing actions of cocaine. The 3-phenyltropane compounds (7) have received paramount 
attention in this regard and have shown increasing promise as pharmacotherapeutics. They have 
been the focus of many drug discovery efforts over the past several years. The detailed SAR of 
this series will be discussed in the following text. 
 
 
1.7 Binding Affinity and Inhibition Constant 
 The drugs are evaluated for their potency by the value of their binding affinity to a 
specific transporter. These values are typically expressed in terms of IC50 or Ki. The value IC50 is 
the concentration at which the compound is needed to displace 50% of the bound radio-labeled 
ligand.97 The radio-labeled ligands used, usually show high affinity for the targeted transporter. 
For example, [3H]WIN-35,428, [3H]citalopram and [3H]nisoxetine are used for the dopamine, 
serotonin and norepinephrine transporters respectively. 
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Ki is the inhibition constant and is related to IC50 by the following equation- 
 
Ki =
IC50
[3H]/ Kd+1  
 
[3H] is the concentration of the radio-labeled ligand used and Kd is the dissociation constant of 
the radio-labeled ligand previously determined for the specific transporter.98 Several factors can 
affect the IC50 values according to experimental conditions which include the type and amount of 
radio-labeled ligand, state of tissue (fresh or frozen), buffer, incubation time, and protein content. 
Therefore, Ki offers a better comparison of data since it takes into account the concentration and 
dissociation constant of the radio-labeled ligand and the IC50 value for the compound. 99 
 
 
1.8 Structure Activity Relationship Studies of 3-Phenyltropanes 
 Initial studies done for the synthesis of pharmacotherapeutics for cocaine abuse were 
based on derivatives of cocaine itself. Studies done by the Clark group resulted in the 
development of WIN-35,065-2 (7) where the benzoyl ester was replaced by a phenyl group 
attached directly to the tropane ring.100 WIN-35,065-2 (IC50 = 23nM) was found to be four times 
more potent than cocaine (IC50 = 89nM) at the dopamine transporter and it provided a new 
molecular template for investigating the pharamacological properties of compounds related to 
cocaine.101 
 WIN-35,065-2 has four sites of asymmetry and eight possible isomers. All probable 
isomers were synthesized and analyzed for dopamine transporter binding, locomotor activity and 
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drug discrimination properties.102 It was found that the 1R isomer is considerably more potent 
than the 1S isomer. These reports also demonstrated that the relative stereochemistry at the 2- 
and 3-position and the absolute configuration of the 3-phenyltropanes are important factors to 
dopamine transporter binding. 
 Early structure activity relationship work on 3-phenyltropanes examined substitution at 
the 4′-position as it plays a critical role in enhancing dopamine transporter affinity. The 4′-fluoro, 
4′-chloro, 4′-methyl, 4′-iodo, 4′-ethylene, 4′-acetylene analogues of WIN-35,065-2 (11a-f) were 
found to have high affinities (Ki values less than 2 nM) at the dopamine transporter (Table 1).103 
Derivatives such as 4′-hydroxy (11i), 4′-nitro (11g), 4′-methoxy (11j), and 4′-amino (11h) 
exhibited IC50 values between 2 and 12 nM at the dopamine transporter (Table 1). Various 
heterocycles were also examined at the 4′- position and were found to exhibit moderate affinity 
for the dopamine transporter.104 An interesting feature of these analogues was that they were 
much more selective for the serotonin transporter than the dopamine and norepinephrine 
transporters. 
The 3′-substituents of WIN 35,065-2 (7) were synthesized and analyzed for their binding 
affinities.105 It was found that 3′-substitution does not affect the dopamine transporter binding 
affinity as significantly as substitution at the 4′-position. For example, addition of halogens (F, 
Cl, Br, I), thiophene, furanyl and phenyl groups at the 3′-position of WIN-35,065-2 yielded 
analogues which were only four- to nine-fold more potent than cocaine.106 
Disubstituion at the 3′, 4′-positions of WIN-35,065-2 was inspected to perceive the 
effects on the dopamine transporter and this series of compounds has provided some of the most 
potent 3-phenyltropanes to date.107 Combinations of 3′- and 4′-chloro, -bromo, -iodo, -fluoro, or 
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–methyl (12 a-m) groups at the 3′, 4′-positions of the phenyl group furnished compounds with 
subnanomolar affinities at the dopamine transporter (<2nM). 108 
 
Table 1. DAT Binding affinity of 4′-substituted analogues of WIN 35065-2 in terms of IC50 values. 
 
N
CO2CH3
H3C
X
(11)  
 
                   IC50 < 2nM              IC50=2-12 nM            IC50=12-30 nM                IC50=30-200 nM 
entry  X entry   X entry  X entry   X 
    a CH3    g NO2    m CF3     s NHCOCH3 
    b Cl    h NH2    n c-CH CHCH3     t NHCO2C2H5 
    c Br    i OH    o O
 
    u CH(CH3)2 
    d I    j OCH3    p S
I  
    v CH2CH CH2
    e -CH CH2     k 
S
Br    q F
 
    w S
 
    f -C CH     l O    r 
N  
    x 
N  
 
  
 17
   
N
CO2CH3
H3C
X
(12)
Y
 X, Y  
a      NH2, I
b      Cl, Cl
c      Cl, CH3
d      Cl, Br
e      Cl, I
f       Br, Cl
g      Br, Br
     X, Y 
h      Br, I
i       I, Cl
j       I, Br
k      I, I
l       CH3, CH3
m     F, CH3
n      NH2, Br  
 
 
Although the halogens are well tolerated at the dopamine transporter, there is a limited 
tolerance for the hydroxyl group. The monosubstituted 3′- and 4′- hydroxyl derivatives exhibited 
dopamine transporter binding affinities around 12 nM whereas the 3′, 4′-dihydroxy analogue (13) 
was found to be 113-fold less potent at the dopamine transporter.109 The catechol derivative (13) 
was prepared to determine if the aryl group of phenyltropanes interacted with the dopamine 
transporter in a similar manner as the 3, 4-dihydroxylphenyl group of dopamine (2). The low 
binding affinity of 13 suggests that dopamine does not occupy the same binding site on the 
dopamine transporter as the 3-phenyltropanes. 
 
 
N
CO2CH3
H3C
OH
(13)
OH
H2N OH
OH
Dopamine (2)  
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 Structural modifications on various 2β-derivatives have received much more attention 
than the 2α-derivatives since they were found to be significantly more potent at the dopamine 
transporter.102 Broad tolerance for a diverse set of amides at the 2β-position of 3β-
phenyltropanes is evident through the variety of analogues which are highly potent and selective 
for the dopamine transporter. The tertiary amides were in general more potent than the 2β-
secondary amides.110, 111 Two noticeable examples are the compounds 14 and 15. 2β-Alkyl and 
2β-alkenyl 3-phenyltropnes were also found to have high affinities at the dopamine transporter 
(16a-d). 112-114 
 
 
N
H3C
Cl
O
N
N
H3C
Cl
O
N O
N
H3C
X
R
(14) (15)
    a, R= -(CH2)2CH3, X=H
    b, R= -CH=CH-Cl, X=Cl
    c, R= -CH=CH-C6H5, X=Cl
    d, R= -CH=CH-CH2-OH, X=H
(16)
 
  
 
Various 2β-ketones were synthesized and evaluated for their potencies at the monoamine 
transporters.115-118 The 2β-propanoyltropanes (17) and the 3β-4′-(2-naphthylphenyl)-2β-acetyl 
(18) were found to be highly potent with IC50 values of 0.15 nM and 0.28 nM, respectively. A 
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series of 2-diarylmethoxy tropanes also displayed high binding affinities and the unsubstituted 
analogue 19 had the highest potency for the dopamine transporter.119    
N
H3C O
N
H3C
Cl
O
CH3
N
H3C
CH3
(17) (18) (19)
CH3
O
 
 
 In order to further define the structural requirements at the 2-position in a better way, 
modifications were done by replacing the carbomethoxy group with substituted aromatic rings. 
The resulting compounds (20a-d) displayed high dopamine transporter affinities and selectivities 
in general with 20a having an IC50 value of 1.96 nM at the dopamine transporter.120 However, a 
compound with a 2-(3, 4-dimethoxyphenyl) group (20d) displayed a 10-fold decrease in affinity 
at the dopamine transporter but improved selectivity over the serotonin and norepinephrine 
transporters. 
 
N
H3C
CH3
R1 R2
(20)
a, R1=H, R2=H
b, R1=H, R2=CH3
c, R1=H, R2=OCH3
d, R1=OCH3, R2=OCH3
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The bioisosteric replacement of the 2β-carbomethoxy group with various heterocyclic 
groups resulted in a class of compounds (21a-d, 22a-d) with DAT affinities ranging from 0.5-26 
nM.121-123 In all cases, compounds with a 3β-(4-methylphenyl) group were less potent at the 
dopamine transporter than compounds having a 3β-(4-chlorophenyl) group. Although in general, 
this series of compounds displayed high potencies and selectivities for the dopamine transporter, 
some compounds appear to have unique pharmacological profiles in vivo. Compounds 21b and 
21c do not produce locomotor stimulation in mice despite having IC50 values of 8.74 nM and 13 
nM respectively at the dopamine transporter. This trend has also been observed for other classes 
of dopamine transporter uptake inhibitors and requires further investigation.124 
 
N
H3C
Cl
R1
N
H3C
R2
N
O
R1
N
O
(21)
a, R1=H, R2=Cl
b, R1=CH3, R2=CH3
c, R1=Cl, R2=CH3
d, R1=CH3, R2=Cl
(22)
C6H5
N
NS
C6H5
O
NN
CH3
N
S
a, R1= b, R1=
c, R1= d, R1=
 
 
 Exchanging the methyl group on the tropane nitrogen with allyl (23a), phenylpropyl 
(23b), iodopropenyl (23c) showed little effect on dopamine transporter binding affinity.125-127 N-
Substituted derivatives 23d and 23e retained high affinity at the DAT and even analogues with 
bulky groups like phthalimido (23f, 23g) were well tolerated.128, 129 This series of N-substituted 
3-phenyltropanes was easy to synthesize and has led to the development of a number of tools to 
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study transporter occupancy and function. Some analogues where R1 is 11CH3 and 
CH2CH2CH218F have been developed as positron emission tomography (PET) ligands.129 
 
N
R1
X
CO2Me
(23)
a, R1=CH2CH=CH2, X=F
b, R1=CH2CH2CH2-C6H5, X=F
c, R1=CH2CH=CH-I, X=F
d, R1=CH2CH2CH3, X=I
e, R1=CH2CH2-F, X=I
f,  R1=(CH2)4-NPht, X=I
g, R1=(CH2)8-NPht, X=I
 
 
A series of bivalent ligands were synthesized having amide linkers separated by spacers 
of 3 to 8 methylene units (24a-d).130 The order of potency increased with increasing spacer 
lengths. The effect of replacement of the 8-aza group on 3-phenyltropanes was investigated and 
it was discovered that 8-carba (25a),131 8-oxa (25b)131 and 8-thia (25c)132 groups did not alter the 
dopamine transporter affinity significantly. Flattening the tropane ring by introduction of a 2, 3-
double bond increased dopamine transporter selectivity over the serotonin transporter.132 The 4′-
substituent on the 3-aryl group affects the dopamine transporter affinity. Replacement of 4′-
chloro (26a) with 4′-bromo (26b), 4′-iodo (26c), 3′, 4′-dichloro (26d) yielded compounds with 
enhanced affinity at the dopamine transporter.  
 
X
Cl
CO2Me
S
R2
CO2Me
R1Cl
(24)
a, n=1
b, n=2
c, n=4
d, n=6
(25)
a, X=CH2
b, X=O
c, X=S
(26)
a, R1=H, R2=Cl
b, R1=H, R2=Br
c, R1=H, R2=I
d, R1=Cl, R2=Cl
N
Cl
H3C
N
Cl
CH3
O
O
NH
NH(CH2)n
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 Conformationally constrained analogues can provide better insights regarding the modes 
of ligand/receptor interactions. A series of tropane macrocyclic derivatives having distinct size, 
hydrophobicity, and electronic properties were synthesized and analyzed for their transporter 
binding affinities.133 One of the most potent ligands at the dopamine transporter was found to be 
27 with IC50 value of 3.8 nM.133  
 Modifications made to the basic tropane framework resulted in compounds with only 
moderate or reduced affinity at the DAT. Both expansion (28)134 and reduction (29)135 of the 
tropane ring by one methylene unit resulted in derivatives with dramatically reduced affinities. 
 
N
NH
H3C
O
O
O
(CH2)5
N
H3C
N
H3CCO2Me
CO2Me
(27) (28) (29)  
 
 A large number of 3-phenyltropanes have been synthesized and analyzed for the purpose 
of selectively modulating the dopamine transporter and consequently provide leads for 
medications for cocaine abuse. Analogues have been developed with high affinity for all three 
transporters and many of these have been evaluated in locomotor activity and cocaine 
discrimination studies. Almost all the compounds investigated show reduction of cocaine self-
administration in both rat and monkey.136, 137 Some analogues are in clinical or advanced pre-
clinical studies for treating cocaine addiction.138 
 Although no compound has been shown to be a useful pharmacotherapeutic for cocaine 
abuse, the development of tropane-based compounds has led to some promising leads for 
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treatment of substance abuse (RTI-336, 30),139 Parkinson’s disease (Brasofensine, 31)140-142 and 
obesity (Tesofensine, 32).143 
 
N
Cl
H3C NO
CH3
N
Cl
H3C N
H
OCH3
Cl
N
Cl
H3C
Cl
OCH3
(RTI-336, 30) (Brasofensine, 31) (Tesofensine, 32)  
 
 
 
1.9 Structure Activity Relationship Studies of Meperidine Analogues 
 Similarities between the symptoms of meperidine (33) intoxication and that of cocaine 
have been well documented.144,145 Meperidine is an atypical µ-opioid receptor agonist and 
chronic exposure to it can produce central nervous system stimulant effects, hyperflexia and 
increased susceptibility to startle.146 These effects are generally specific to meperidine and 
usually are not observed with other µ-opioid receptor agonists such as morphine (34).147  
 
NH3C
CO2CH2CH3
(Meperidine, 33)
O
HO
HO
H
N
(Morphine, 34)  
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 Meperidine shares numerous structural features with cocaine and the phenyltropane 
analogues of cocaine.148 The piperidine ring is a common ring structure in both meperidine and 
cocaine congeners. Furthermore, N-methyl group occurs in meperidine as well as cocaine and the 
phenyltropane series of compounds. The phenyl ring attached to the 3-position on the tropane 
ring of the WIN 35065-2 (7) is equivalent to the phenyl substituent on the 4-position of the 
piperidine ring of meperidine. These common structural features between meperidine and the 
cocaine congeners combined with the unique pharmacological profile of meperidine suggested 
that the non-opioid actions of meperidine could be due to a cocaine-like pharmacological 
action.148 However, in cocaine discrimination studies, neither meperidine nor morphine alone 
produced a substitution for cocaine in animals trained to distinguish cocaine from saline.148 
Nevertheless, pretreatment with 0.1 mg/kg naltrexone (35) improved the effectiveness of 
meperidine and produced cocaine-like discriminative stimulus effects in monkeys, whereas 
morphine was inactive under similar conditions. Naltrexone alone has not been known to 
substitute for cocaine.148  
 
O
OH
O
OH
N
(Naltrexone, 35)  
  
In further studies, both cocaine and meperidine inhibited [3H]dopamine uptake with comparable 
potencies. Morphine did not inhibit [3H]dopamine uptake, indicating that the effect of 
meperidine was not via a classic µ-opioid receptor agonist. This data suggests that these actions 
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of meperidine which are atypical of opioids are due to activity at the dopamine and serotonin 
transporters. Moreover, meperidine appears to interact primarily with the high-affinity 
component of the dopamine transporter. In the absence of other known dopamine uptake 
inhibitors that can discriminate between high-affinity and low-affinity sites at the dopamine 
transporter, the data from meperidine binding provides valuable information. The high-affinity 
component of the response curve of meperidine resembled the high-affinity component of the 
inhibition of dopamine uptake produced by cocaine and this suggests that this high-affinity 
component may be the site of importance for the production of cocaine’s behavioral effects.148 
 To further explore the selectivity for the high-affinity cocaine binding site, a series of 
meperidine analogues with variations at the aromatic ring were synthesized and analyzed by 
Trudell et al (36a-f).149 Compounds that could allow discrimination of high- and low-affinity 
sites at the dopamine transporter would be useful probes to investigate the subjective effects of 
cocaine.  
 
 
NH3C
CO2CH2CH3
Ar
F
Cl
I
CH3
Cl
Cl
a, Ar=
b, Ar=
c, Ar=
d, Ar=
e, Ar=
f, Ar=
(36)
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All the analogues (36a-f) exhibited marked increase in dopamine and serotonin 
transporter selectivity over µ-opioid receptors compared to meperidine (Ki, DAT= 18 µM, Ki, 
SERT= 0.41 µM). The 2′-naphthyl derivative (36f) was 60-fold more potent at the serotonin 
transporter than mepridine and exhibited the greatest selectivity for the serotonin transporter over 
the µ-opioid receptors. The 3, 4-dichloro analogue (36e) was found to be the most potent ligand 
of the series at the dopamine transporter (Ki = 0.125 µM) and displayed the highest selectivity for 
the dopamine transporter over that of µ-opioid receptors. Both 36e and 36f proved to be 
important ligands for differentiating between the high- and low-affinity components at the 
dopamine transporter as well. All the compounds in the series exhibited reduced affinity for µ-
opioid receptors relative to the parent compound, meperidine. In general, the SAR of these 
meperidine derivatives at the dopamine transporter exhibited a similar trend to that of the 
phenyltropanes. The naphthyl and the 3,4-dichloro derivatives were also tested for their 
locomotor-stimulant activity in mice but they did not produce any locomotor effects or substitute 
for cocaine in drug discrimination studies. This could be attributed to the fact that both these 
compounds still exhibited considerable µ-opioid effects (Ki = 2.04 µM for 36e and Ki = 2.03 µM 
for 36f).149 
  As the 3, 4-dichlorophenyl group proved to be an important structural moiety for 
recognition at the dopamine transporter; further SAR studies were done using 36e as a molecular 
scaffold. A series of modified ester and N-substituted analogues was synthesized and evaluated 
for dopamine and serotonin transporter binding affinities.150 In general the ester analogues (37a-
h) demonstrated almost equal binding affinities at the serotonin transporter relative to 36e. The 
small-branched esters (37c and 37e) exhibited equivalent affinity to the ethyl ester 36e but long-
chain esters (37d and 37f), and sterically demanding esters (37g and 37h), displayed poor 
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binding affinities at the dopamine transporter. This trend was unlike the 3-phenyltropanes that 
can tolerate a variety of esters at the 2-position of the tropane system. In the meperidine 
analogues (37a-h), a slight alteration of the ester group resulted in a noteworthy loss of affinity 
at the dopamine transporter. Conversely, the increase in the size of the ester chain of 36e led to 
an increased affinity at the serotonin transporter. Particularly, the benzyl ester (37h) proved to be 
the most potent and selective meperidine-related ligands at the serotonin transporter.150 
 
NH3C
CO2R1
(37)
Cl
Cl
a, R1=CH3
b, R1=CH2CH2CH3
c, R1=CH(CH3)2
d, R1=CH2(CH2)2CH3
e, R1=CH(CH3)CH2CH3
f, R1=CH2(CH2)3CH3
g, R1=CH2CH2CH(CH3)2
h, R1=CH2C6H5
 
  
 
Substituting the N-methyl group with various N-alkyl, N-alkyl-aryl, N-alkenyl and N-
alkynyl groups led to decreased affinities at the dopamine transporter. The least potent 
compounds of the series were the N-benzyl 38a and the N-chloro-propenyl 38n congeners.150 
 
 
NR1
CO2Et
(38)
Cl
Cl
a, R1=CH2Ph
b, R1=CH2(CH2)2Ph
c, R1=CH2(E)-CH=CHPh
d, R1=CH2CH3
e, R1=CH2CH2CH3
f, R1=CH2C    CH
g, R1=CH2-c-Pr
h, R1=CH2CH2CH2Cl
 
 
 The SAR of the meperidine derivatives was further surveyed by converting the ester 
moiety into different functional groups. Conversion into the ketones (39a and 39b) resulted in 
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analogues with reduced affinity for both the dopamine and the serotonin transporters. The 
alcohol congeners (39c and 39g) exhibited decreased dopamine transporter binding but displayed 
equipotent-binding affinity at the serotonin transporter relative to 36e. The 4-vinyl (39d) and 4-
ethyl (39e) derivatives were the most potent ligands of this series at the serotonin transporter. 
This study shows that the ester moiety is not a required group for high affinity binding and a 
variety of functionalities can be tolerated at the 4-position of the meperidine analogues.150 
 
 
NH3C
R1
(39)
Cl
Cl
a, R1=C(O)CH3
b, R1=C(O)Ph
c, R1=C(OH)CH3
d, R1=CH=CH2
e, R1=CH2CH3
f, R1=CH2OAc
g, R1=CH2OH
 
 
 
 
1.10 Design Strategy for Novel Tropane Analogues 
 In recent reports it has been demonstrated that meperidine can fully substitute for cocaine 
in squirrel monkeys under certain specific conditions.148 SAR studies of various aryl and N-
substituted meperidine analogues has revealed that these compounds have considerably 
significant activity at the neural transporters and almost all the congeners displayed an inherent 
serotonin transporter selectivity over the dopamine transporter. Different esters and various 
functional groups were also well tolerated and exhibited the same trend of selectivity as other 
meperidine analogues.    
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In the last decade, a lot of research was focused on synthesizing only dopamine 
transporter selective compounds, which ultimately did not provide a viable therapeutic for drug 
abuse. However, now it is well established that cocaine is a ‘dirty’ drug and interacts with all the 
three transporters (dopamine, serotonin and norepinephrine). The effects of the aryl substitution 
on the dopamine transporter affinity of the meperidine analogues paralleled the SAR of 
phenyltropane analogues which typically exhibit high dopamine transporter potency and 
selectivity. The main goals of this research were to design a series of ligands that could be 
equipotent for both the dopamine and serotonin transporters and provide leads for developing 
pharmacotherapeutics to treat cocaine abuse. It was envisioned that target compounds could be 
synthesized which would incorporate the rigidity of the tropane system with the design of the 
meperidine analogues in an attempt to increase the dopamine transporter affinity of these novel 
compounds.   
Although SAR studies of the basic meperidine structure are well documented, no work 
has been carried out to identify the conformation adopted on binding to the dopamine transporter 
or the serotonin transporter. Meperidine has significant structural flexibility and can exist in both 
chair and boat conformations. It was of interest to study ring constrained analogues in which the 
important pharmacophore was held rigid to gain better insights into the conformation adopted 
while binding to the transporters. Moreover, almost all the meperidine analogues showed µ-
opioid receptor activity and since none of the analogues tested, produced locomotor effects or 
substituted for cocaine completely in drug discrimination studies, it was suggested that the µ-
opioid effects may be playing a role in their activity. Incorporating the design of the 
phenyltropane ring system with the meperidine structure could provide important compounds 
that would lack activity at the µ-opioid receptors, have a rigid conformation and could 
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conceivably have affinity for both the dopamine and the serotonin transporters. Affinity for the 
norepinephrine transporter is not preferred since it can lead to heart disorders and other 
cardiovascular problems. Based upon this rationale, the target molecules were designed as hybrid 
structures of 3β-phenyltropanes and meperidine (Figure 3). 
 
N
H3C
N
H3C
R= CH3, C2H5,
R
,
X
R
NH3C
R
X
DAT Selective SERT Selective
X
DAT/SERT = 1
     No NET
X= H, Cl, F, CF3, 3,4-Cl2
(43)
 
 
Figure 3. Target compounds as hybrid structures of 3β-phenyltropanes and meperidine. 
  
The retrosynthetic analysis for the synthesis of the target compounds with alkyl and allyl 
esters is outlined in Scheme 1. The synthesis was envisaged to start from the commercially 
available 3-tropinone (40). The carbonyl group could be used in the Grignard reaction to furnish 
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the tertiary alcohol (41). Functional group conversion could yield the cyano derivative (42). The 
nitrile could then be converted into the corresponding ester via a two-step reaction sequence to 
furnish the target products (43). 
 
 
N
X
H3C
CO2R
N
X
H3C
CN
N
X
H3C
OH
N
H3C
O
(40)
(41)(42)(43)
BrMgPh-X
TMSCNH2SO4/H2O
ROH
R= CH3, C2H5, ,
X= H, Cl, F, CF3, 3,4-Cl2
 
 
Scheme 1. Retrosynthetic analysis for the preparation of target molecules with alkyl and allyl esters. 
 
 
Additionally, an array of benzyl esters and benzyl ethers was designed since it was 
previously discovered from the SAR of meperidine analogues that the benzyl group is an 
important structural feature for enhancing potency and selectivity at the dopamine and the 
serotonin transporters. The benzyl esters (44) could be prepared from the methyl ester derivative 
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of 43 via N-heterocyclic carbene catalyzed transesterification method (Scheme 2). The benzyl 
ethers 45 could be prepared from direct alkylation of 41 (Scheme 2). 
 
 
N
X
H3C
CO2CH3
N
X
H3C
OO
X
(44) (43)
N
H3C
OH
(41)
X
N
H3C
O
X
X
(45)  
 
 
Scheme 2. Retrosynthetic analysis for the preparation of target molecules with benzyl esters and benzyl ethers. 
 
 
From previous studies of meperidine derivatives it was found that the N-H group is a key 
structural feature for the molecular recognition at the serotonin transporter as well as for 
differentiating between the serotonin and the dopamine transporters. This suggested that the N-H 
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analogues of the target compounds could exhibit potent and selective serotonin transporter 
affinity. Analogues with high serotonin transporter affinity and selectivity could then be 
developed as potential serotonin selective reuptake inhibitors (SSRIs), useful for the treatment of 
a variety of neurological disorders, which include depression, schizophrenia and post-traumatic 
stress syndrome. The retrosynthetic strategy for the synthesis of the N-H analogues 46 is shown 
in Scheme 3. 
 
 
N
X
H3C
R
N
X
H
R
(46) 44, R = CO2CH2C6H4-X
45, R = OCH2C6H4-X  
 
Scheme 3. Retrosynthetic analysis for the preparation of N-H analogues. 
 
 
 
 
 
 
 
 
 
 
 
 34
RESULTS AND DISCUSSION 
 
2.1 Attempted Synthesis of 3-Aryl-3-carbomethoxytropane and its Analogues. 
Several synthetic routes were investigated to prepare the target molecules 3-aryl-3-
carbomethoxy tropane and its derivatives. The first step of the approach was to transform the 
commercially available 3-tropinone (40) into a 3-phenyl-3-hydroxytropane (41a). The reaction 
was performed by reacting the commercially available Grignard reagent, phenylmagnesium 
bromide in ether, with the tropinone (40) at -78οC.151 
 
N
H3C
N
H3C
OHO
(40) (41a)
PhMgBr
Et2O, -78
οC, 3h
 
 
 Some problems were encountered regarding the purification of the product because the 
starting ketone and the resulting product exhibited similar polarity in many solvent systems used 
for separations column chromatography. A pure product was obtained using Kuglrohr distillation 
apparatus in 20% yield. The Kuglrohr distillation method of separation allowed for the complete 
recovery of the unreacted starting material. In an attempt to increase the yield, a different 
reaction solvent system was utilized. It was discovered that employing tetrahydrofuran instead of 
diethyl ether as the reaction solvent did not improve the yield significantly. Varying the reaction 
conditions and temperature led to performing the reaction at reflux in tetrahydrofuran. However, 
only 4% product was obtained after 24 hours under these modified conditions. 
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 Since separation of the desired product (41a) from tropinone (40) by the distillation 
method was efficient on a small scale only (1 gram), the need for large quantities (5-10 grams) 
led to exploration of a different method of separation. It was envisaged that the reduction of the 
unreacted tropinone in the reaction mixture to an alcohol would change the relative polarity of 
compounds to be separated and hence facilitate purification of the product by column 
chromatography (Scheme 4). This method furnished the desired product (41a) in 27% yield by 
employing mixtures of ethyl acetate, hexanes and chloroform as eluent for purification by 
column chromatography. 
 
N
H3C
N
H3C
OHO
(40)
NaBH4
unreacted starting material
CH3OH
(47)
 
 
Scheme 4. Reduction of the unreacted starting material. 
  
 Since the yield of the resulting 3-phenyl-3-hydroxytropane was not very high, a more 
reactive aryllithium reagent was used for the transformation. To that end, n-BuLi (2.5 M in 
hexanes) and bromobenzene was used to freshly prepare phenyllithium and then add 3-tropinone 
to the same flask, making it a one-pot reaction. The change of reagents led to an improvement by 
affording the product in 38% yield (Scheme 5). Although, the improvement in the yield was 
modest, on a large scale it translated to a difference of grams. Therefore, freshly prepared lithium 
reagents were used for this and future transformations. 
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N
H3C
N
H3C
OHO
THF, -78oC, 3h
Li
Br n-BuLi
(40) (41a)THF, -78
oC, 2h
 
 
 
Scheme 5. Use of freshly prepared phenyllithium reagent for transforming 3-tropinone. 
 
 It appears that the use of n-BuLi displayed a positive effect on enhancing the yield of the 
reaction; to this end, reactivity of n-BuLi was investigated. n-BuLi exists mainly in the 
hexameric form in hydrocarbon solvents such as hexanes.152 Chelating ligands such as 
tetramethylethylenediamine (TMEDA) can reduce the degree of aggregation of n-BuLi and favor 
the formation of monomeric solvated species thus increasing the reactivity.153 Other reagents 
which can improve the reactivity of alkyllithium reagents are strong donor molecules for 
example hexamethylphosphorictriamide (HMPA) and N, N-dimethylpropyleneurea (DMPU)154 
shown in Figure 4. 
N NH3C
CH3 CH3
CH3
N
N
O
CH3
CH3
P
O
N
N
N
H3C
H3C
H3C CH3
CH3
CH3
(TMEDA) (HMPA) (DMPU)  
 
Figure 4. Structures of some chelating ligands used to enhance reactivity of the alkyllithium reagents. 
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 TMEDA was used with n-BuLi to convert 3-tropinone into the desired product (41a) but 
it was discovered that it did not enhance the yield considerably.155 Therefore, further 
transformations were carried out only in the presence of n-BuLi. 
With the hydroxyl tropane 41a in hand, the next step, functional group transformation of 
the hydroxyl group into the nitrile was investigated (Scheme 6). 
 
N
H3C
OH
(41a)
N
H3C
CN
TMSCN, CH2Cl2, rt
(42)  
 
Scheme 6. Attempted functional group interconversion of the hydroxyl group to the nitrile. 
 
Attempts to convert 41a into 42 did not yield the desired product. A variety of reaction 
conditions were investigated where the use of a catalyst (zinc iodide) was employed and the 
temperature was lowered to -78oC.156 These changes also did not result in the formation of the 
cyano tropane derivative. In situ generation of trimethylsilylcyanide (TMSCN) was attempted by 
employing a mixture of sodium cyanide, sodium iodide and trimethylsilychloride and using it for 
the transformation of the hydroxyl group to the cyano group, but it failed to give the desired 
product.157 The crude reaction mixtures from all the above attempts indicated the complete 
consumption of the starting material and generation of another product. An investigation 
conducted to identify the product revealed that β−elimination was occurring to yield 48 as the 
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major product (Scheme 7). Several variations of the solvent, temperature profile and reagents 
also resulted in the formation of the β−elimination product instead of the desired cyano tropane 
derivative. 
 
 
N
H3C
(48)
N
H3C
O
H
H
Nu
(41a)
H TMS
 
 
Scheme 7. Formation of the unsaturated compound via β-elimination. 
 
 
2.2 Attempted Synthesis of 3-Aryl-3-propyltropane and its Analogues. 
From previous SAR studies, it was known that the ester moiety is not a required 
structural feature for molecular recognition at the monoamine transporters and a variety of 
functional groups can be tolerated at the recognition site. Based on this information, another 
route was devised to obtain products that could be useful as ligands for both the dopamine and 
the serotonin transporters. Incorporation of an allyl group instead of the ester moiety was 
envisaged by reacting the hydroxy tropane (41) with methylchlorooxoacetate and treating the 
resulting product with tributylallylstannane (Scheme 8). The 3-aryl-3-allyl tropane derivatives 
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(50) could easily be converted to the propyl analogues (51) by hydrogenating the double bond 
thus providing a series of compounds with variations at the aryl group.  
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Scheme 8. Retrosynthetic analysis for the formation of 3-aryl-3-propyl-tropane analogues. 
 
 
 Initially, n-BuLi was utilized to deprotonate 41a and then reacting with methyl oxalyl 
chloride to obtain the oxalate derivative 49a in a one-pot procedure158 (Scheme 9). After 
considerable experimentation with variations in temperature, time and reagent quantities, the 
desired product was not obtained. Alternatively, either the elimination product (48) or the 
unreacted starting material (41a) or a mixture of both was obtained. 
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Scheme 9. Attempted functional group interconversion of the hydroxyl group into the oxalate. 
 
 
2.3 Synthesis of 3-Aryl-3-methoxytropane and its Analogues. 
Since any changes requiring the carbon–oxygen bond cleavage resulted in a β-elimination, 
efforts were redirected toward performing transformations involving the oxygen-hydrogen bond 
of the hydroxyl tropane (Figure 5). 
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bond might yield desired products
 
Figure 5 
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 The simplest transformation to functionalize the hydroxyl group is to convert it into an 
ether moiety. A retrosynthetic strategy was devised to do the same, starting from the hydroxyl 
tropane 41a and then synthesizing the analogues with different substituents at the aryl ring. 
 
N
H3C
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N
H3C
O
R
R-X
(41a)(52)  
 
Scheme 10. Retrosynthetic route for the synthesis of 3-phenyl-3-methoxytropane and its analogues. 
 
 3-Phenyl-3-hydroxy tropane (41a) was reacted with dimethylsulphate in the presence of a 
base under an inert atmosphere. Analysis of the reaction mixture revealed that quarternerization 
of the tertiary amine had occurred and the desired product was not recovered (Scheme 11). 
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Scheme 11. Quarternerization of the tertiary amine. 
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To obtain the 3-aryl-3-methoxytropane analogues, the tertiary amine was required to be 
protected in order to reduce the basicity of the nitrogen of the tropane. As shown in Scheme 12, 
the amine of 3-tropinone was protected using ethylchloroformate. The protected tropinone (54) 
was transformed into tertiary alcohols (55) using in situ generated organolithium reagents. The 3-
phenyl-3-hydroxytropane derivatives (55) underwent a smooth transformation into the desired 
methyl ethers (56). The protecting group was converted into the N-methyl group using lithium 
aluminium hydride reduction to yield the desired final products (57). Following the synthetic 
route in Scheme 12, the derivatives of 57 were synthesized with different halogen substituents at 
the 4-position of the aryl ring. Each pure analogue was then converted into the oxalate salt for 
biological evaluation. 
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Scheme 12. Synthetic route for the synthesis of 3-aryl-3-methoxytropane derivatives. 
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Crystallographic data for the tertiary alcohol (55a) was obtained to confirm the 
stereochemistry at the 3-position (Figure 6). It was revealed from the X-ray structure that the 
phenyl ring occupies the β-position at C3 and the hydroxyl group is in the 3α-position of the 
tropane ring structure. This served to unequivocally establish the relative stereochemistry of the 
nucleophilic addition of the phenyllithium to 3-tropinones 40 and 54. 
 
 
 
 
 
Figure 6. X-ray structure of 3β-phenyl-3-hydroxytropane (55a) provided courtesy of Prof. Edwin D. Stevens. 
 44
The transporter binding affinities were determined for some of the 3-aryl-3-methoxy 
tropane analogues (57) and for a few of the hydroxyl derivatives (41) and are depicted in Table 
1. The binding affinity values were obtained by the ability of the compounds to displace bound 
radiolabeled ligands from rat caudate-putamen tissue. The Ki values reported in Table 1 are the 
inhibition constants derived from the unlabeled ligands. The binding affinities of the novel 
tropane analogues were determined at the dopamine transporter (DAT) by inhibition of 
[3H]WIN- 35,428 and at serotonin transporter (SERT) by inhibition of [3H]citalopram.  
 
Table 2. In vitro data for derivatives of 3-aryl-3-methoxytropane and 3-aryl-3-hydroxytropane. 
Compounda 
[3H]WIN 35428 
(DAT) Ki (nM)b 
[3H]citalopram 
(SERT) Ki (nM)b 
DAT/SERT 
N
H3C
OH
Cl
41b  
  32,000 ± 2,000   12,000 ± 1500       2.7 
N
H3C
OH
Cl
Cl
41e  
    4,120 ± 600     1,600 ± 80       2.6 
N
H3C
O
Cl
57b  
   9,600 ± 1,000    1,370 ± 130       7.0 
N
H3C
O
Cl
Cl
57e  
     900 ± 100      300 ± 60       3.0 
       a All compounds were tested as oxalate salts. b All the values are mean ± SEM of three experiments  
        performed in triplicate. 
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 In general, the derivatives evaluated for binding affinity did not prove to be highly potent 
at either the dopamine or the serotonin transporter. Binding affinity at the norepinephrine 
transporter was not determined due to the low potency at the other transporters. The 3, 4-Cl2 
substituted alcohol (41e) was almost 8-fold more potent than the 4-chloro substituted alcohol 
(41b). Similarly, the 3, 4-Cl2 substituted methoxy tropane (57e) was 10-fold more potent than the 
4-chloro substituted methoxy tropane (57b). All the analogues in general were more selective for 
the serotonin transporter than the dopamine transporter.  
 The 3, 4- Cl2 aryl substituted methyl ester analogue of meperidine , 37a (Ki = 383 nM), 
was only 2.5 times more potent than ring constrained methoxy ether analogue 57e (Ki = 900 nM) 
at the dopamine transporter but 37a was significantly more potent at the serotonin transporter (Ki 
= 15.4 nM) than 57e. The binding affinity at the dopamine transporter of the alcohol derivative 
of the 3, 4- Cl2 aryl substituted meperidine, 39g (Ki = 3310 nM), was in the micromolar range 
along with the tropane derivative 41e (Ki = 4120 nM). 
 From the previous SAR of the substituted meperidine analogues, it was discovered that 
the benzyl ester derivative 37h, displayed an enhanced potency at the serotonin transporter over 
other alkyl esters and is the most selective meperidine analogue reported to date (Ki = 3.9 nM, 
DAT/SERT = 760). Therefore, the benzyl ether analogues of the tropane system were 
synthesized to determine if the benzyl group can enhance potency of the tropane analogues at the 
monoamine transporters as well. 
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2.4 Synthesis of 3-Aryl-3-arylmethoxytropane Derivatives. 
 The synthesis of 3-aryl-3-arylmethoxytropane analogues was achieved by following a 
synthetic route similar to the one for the methoxy derivatives 57. As illustrated in Scheme 13, the 
tertiary alcohols (55a-e) were treated with sodium hydride and the desired benzyl halides to 
afford the benzyl ethers 58. Compounds 58 were deprotected using hydrazine, potassium 
hydroxide and ethylene glycol to afford the desired products 59. These compounds were further 
modified by replacing the N-H group with an N-methyl group using formaldehyde and sodium 
cyanoborohydride to yield compounds 60.  
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Scheme 13. Synthetic route for the synthesis of 3-aryl-3-arylmethoxytropane derivatives. 
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An array of compounds could be synthesized using different combinations of the halide 
substituents on the aryl rings. Compounds 59a-e and 60a-e were obtained by reacting different 
tertiary alcohols (55a-e) with benzyl bromide, and the subsequent removal of the protecting 
group resulted in a series of compounds with benzyl ether as a substituent in the 3α position of 
these tropane derivatives (Figure 7). Compounds 59a-e, the N-H derivatives, were obtained in 
70-92% yields and the corresponding N-methyl analogues, 60a-e, were obtained in 79-87% 
yields.  
 
 
NR
O
Cl
Cl
NR
O
CF3
NR
O
F
NR
O
Cl
NR
O
59a, R=H
60a, R=CH3
59b, R=H
60b, R=CH3
59c, R=H
60c, R=CH3
59d, R=H
60d, R=CH3
59e, R=H
60e, R=CH3  
 
Figure 7. Benzyl ether analogues, 59a-e and 60a-e. 
 
 
 Similarly, another series of novel tropane compounds was prepared by using 3, 4-
dichlorobenzyl chloride to react with the various tertiary alcohols (55a-e). The series of N-H 
analogues, 59f-j, were obtained in 85-93% yields. Treatment of these compounds with 
formaldehyde/sodium cyanoborohydride afforded the N-methyl derivatives, 60f-j, in 75-90% 
yields (Figure 8). 
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 Figure 8. Benzyl ether analogues, 59f-j and 60f-j. 
  
A number of other novel tropane derivatives were synthesized in a similar manner. The 
variations in the tertiary alcohol (55a-e) and the desired benzyl halide used, afforded another 
array of N-H compounds, 59k-q in 72-86% yields. These were also converted into the 
corresponding N-methyl derivatives (60k-q) and were obtained in 74-88% yields (Figure 9). 
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Figure 9. Benzyl ether analogues, 59k-q and 60k-q. 
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 Crystallographic data for the N-methyl derivative, 60a (as an oxalate salt), was obtained 
to confirm the stereochemistry of the substituents at the 3-position (Figure 10). The X-ray 
structure clearly shows that the phenyl ring occupies the β position at C3 and the phenylmethoxy 
group is in the α position. The stereochemistry of the groups is retained from the tertiary alcohol 
55a (Figure 5). This data unequivocally establishes the relative stereochemistry of novel 3β-aryl-
3α-arylmethoxytropane analogues 60.   
 
 
Figure 10. X-ray structure of 3β-phenyl-3α-phenylmethoxytropane (60a) provided courtesy of Prof. Edwin D.  
Stevens. 
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Transporter binding affinities for several of the novel 3-aryl-3-arylmethoxytropane 
derivatives were determined by their ability to displace bound radiolabeled ligands from rat 
caudate-putamen tissue. The Ki values for some of the analogues of 59 are presented in Table 3. 
The data for derivatives of 60 are summarized in Table 4. They were determined by similar 
methods as previously reported in Table 1. 
 
Table 3. In vitro binding data at the DAT and the SERT for 3β-aryl-3α-arylmethoxynortropane derivatives. 
NH
O
Z
W
X
Y
 
   Compounda   W, X, Y, Z 
[3H]WIN 35,428 
(DAT) Ki (nM)b 
[3H]citalopram 
(SERT) Ki (nM)b 
   DAT/SERT 
     Cocaine  
        32 ± 5 
      388 ± 221 
  
        59a   H, H, H, H       120 ± 20       250 ± 30            0.48 
        59f   H, H, Cl, Cl         16 ± 1    0.061 ± 0.024        266 
        59j   Cl, Cl, Cl, Cl    2,800 ± 640        4.7 ± 0.3        600 
        59l   Cl, H, H, Cl         63 ± 7    0.096 ± 0.022        653 
        59m   CF3, H, H, Cl     3,000 ± 730           6 ± 2        500 
        59n   F, H, H, F       100 ± 10        7.7 ± 3.6          13 
        59o   CF3, H, H, CF3    5,000 ± 900        2.0 ± 1.6      2500 
a All compounds were tested as oxalate salts. b All the values are mean ± SEM of three experiments  
  performed in triplicate. 
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Table 4. In vitro binding data at the DAT and the SERT for 3β-aryl-3α-arylmethoxy-8-methyltropane derivatives. 
NH3C
O
Z
W
X
Y
 
   Compounda   W, X, Y, Z 
[3H]WIN 35428 
(DAT) Ki (nM)b 
[3H]Citalopram 
(SERT) Ki (nM)b 
   DAT/SERT 
        60a   H, H, H, H       96 ± 20       140 ± 7           0.68 
        60j  Cl, Cl, Cl, Cl  2,300 ± 230       9.6 ± 3.6       240 
        60l  Cl, H, H, Cl     760 ± 70     18.0 ± 0.7         42 
        60m  CF3, H, H, Cl  4,800 ± 1,700       100 ± 10         48 
        60n  F, H, H, F     900 ± 70        4.8 ± 1.3       188 
        60o  CF3, H, H, CF3  3,800 ± 630        7.4 ± 3.2       515 
a All compounds were tested as oxalate salts. b All the values are mean ± SEM of three experiments  
  performed in triplicate. 
 
 
 In general, the N-H analogues (Table 3) were found to be more potent and selective for 
the serotonin transporter than the dopamine transporter with the exception of 59a, which 
displayed slight selectivity for the dopamine transporter over the serotonin transporter 
(DAT/SERT = 0.48). Most notably, compounds 59f (Ki = 0.061 nM) and 59l (Ki = 0.096 nM) 
were the most potent ligands of the series at the serotonin transporter. The binding affinities of 
59f and 59l are in the subnanomolar range which makes them amongst the most potent ligands 
for the serotonin transporter reported to date. The binding affinity of 59f and 59l exceeded the 
potency of the radiolabeled ligand citalopram, (Ki = 2 nM)159 used for obtaining this data. 
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Moreover, 59f and 59l were equipotent with paroxetine (Paxil®, SERT Ki = 0.2 nM),159 a widely 
prescribed serotonin selective reuptake inhibitor for the treatment of depression. These two N-H 
analogues also displayed high potency for the dopamine transporter and 59f (Ki = 16 nM) was 
four times more potent than 59l (Ki = 64 nM) and was also the most potent ligand of the series 
for the dopamine transporter. From this data, it appears that chlorine is an important substituent 
on the aryl rings of these tropane analogues for molecular recognition at both the monoamine 
transporters, serotonin and dopamine, as it enhances the potency at these transporters 
substantially.  
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The N-H analogues, 59j, 59m, 59n and 59o exhibited potent serotonin transporter affinity 
but displayed poor dopamine transporter affinity. Analogue 59o, with trifluoromethane group as 
substituents on both the aryl rings, displayed the highest selectivity for the serotonin transporter 
in the series (DAT/SERT = 2,515). The binding affinity at the dopamine transporter dropped in 
the micromolar range for the 3, 4-dichloro substituted derivative, 59j (Ki = 2,800 nM), the 
trifluoromethane substituted derivative, 59o (Ki = 5,000 nM), and the analogue with 
trifluoromethane and chlorine groups, 59m (Ki = 3,000 nM). Compound 59n (Ki = 100 nM), 
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which has the smallest halide, fluorine, as a substituent on both the aryl rings, is equipotent with 
the unsubstituted N-H analogue, 59a (Ki = 120 nM), at the dopamine transporter but 59n (Ki = 
7.7 nM) is considerably more potent at the serotonin transporter than 59a (Ki = 250 nM). From 
this data it appears that while the serotonin transporter can tolerate a range of functional groups, 
the dopamine transporter cannot accommodate strong electron withdrawing groups like 
trifluoromethyl on the aryl rings of the tropane derivatives. However, the high affinity observed 
for 59o at the serotonin transporter is consistent with the SAR of potent SSRI fluoxetine 
(Prozac®).160 
 
O
N
H
Me
CF3
Fluoxetine  
  
The N-methyl analogues (Table 4) were in general less potent at both the dopamine 
transporter and the serotonin transporter than the corresponding N-H derivatives. However, the 
same trend in selectivity of the serotonin transporter over the dopamine transporter was observed 
in this series of ligands as well. Compound 60a which has unsubstituted phenyl rings, was the 
exception, displaying a slight preference for the dopamine transporter over the serotonin 
transporter (DAT/SERT = 0.68). The most potent compounds of this series at the serotonin 
transporter were the fluoro substituted 60n (Ki = 4.8 nM), the trifluoromethane substituted 60o 
(Ki = 7.4 nM) and the 3, 4-dichloro substituted 60j (Ki = 9.6 nM), whereas the least potent were 
the unsubstituted N-methyl analogue, 60a (Ki = 140 nM) and the derivative with 
trifluoromethane and the chlorine groups, 60m (Ki = 100 nM). The N-methyl analogue having a 
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chloride group on both the aryl rings, 60l, displayed a reduced affinity for both the dopamine 
transporter (Ki = 760 nM) and the serotonin transporter (Ki = 18 nM) as compared to its N-H 
counterpart, which was one of the most potent ligands for both the transporters in the series. 
Replacing one of the chlorine groups of 60l with a trifluoromethane group resulted in 60m, 
which displayed a further drop in the binding affinities at the dopamine transporter (Ki = 4,800 
nM) and also at the serotonin transporter (Ki = 100 nM).     
 In summary, the results of this study clearly demonstrate that 3β-aryl-3α-
arylmethoxytropane derivatives are selective ligands for the serotonin transporter over the 
dopamine transporter. Moreover, the N-H analogues were found to be more selective and potent 
than the N-methyl derivatives for the serotonin transporter and the dopamine transporter. Most 
notably, the N-H derivatives, 59f and 59l, exhibited the highest potency for the serotonin 
transporter reported to date. They are equipotent with paroxetine and fluoxetine, which are 
widely prescribed serotonin selective reuptake inhibitors for the treatment of depression. This 
suggests that these analogues could be developed as potential therapeutics for treating 
depression. Since both 59f and 59l also displayed the highest potency for the dopamine 
transporter in both the series of compounds, it appears that chlorine is an important substituent 
for molecular recognition at both the dopamine transporter and the serotonin transporter. Also, 
analogue 59o was the most selective ligand for the serotonin transporter over the dopamine 
transporter in the series. In general, the serotonin transporter tolerated a wide range of functional 
groups but the dopamine transporter affinities were moderate and mainly in the micromolar 
range. The unsubstituted analogues, 59a and 60a, were the only compounds which exhibited a 
slight selectivity for the dopamine transporter over the serotonin transporter, which suggests that 
electron withdrawing groups could be necessary for recognition at the serotonin transporter. 
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Despite some structural similarities to the dopamine transporter selective 2-substituted-3β-
phenyltropanes, these novel 3β-aryl-3α-arylmethoxy derivatives retained the inherent serotonin 
transporter selectivity of meperidine and exhibited more potent affinity for the serotonin 
transporter and were significantly less potent at the dopamine transporter than the corresponding 
2-substituted-3β-aryltropanes. Overall, this investigation suggests that the chloro-substituted aryl 
rings at the 3-position of tropane is a key structural feature for molecular recognition at the 
serotonin transporter as well as differentiation between the serotonin transporter and the 
dopamine transporter. The biology data of more compounds in these series will elucidate further 
structure-activity relationships and help to optimize the serotonin transporter selectivity. 
Moreover, the effect of the relationship of various substituents on both the aryl rings of 3β-aryl-
3α-arylmethoxytropane analogues will be evaluated more comprehensively. In addition, various 
serotonin transporter selective ligands will be evaluated to determine if the incorporation of the 
design of tropane motif to the meperidine structure has led to diminished µ-opioid receptor 
affinity. 
 
 
2.5 Synthesis of Novel 3-Aryl-2-nortropene Derivatives as Triple Reuptake                     
Inhibitors. 
 Monoamine re-uptake inhibition has been one of the important neuropharmacological 
approaches for the treatment of depression. The monoamines, dopamine, serotonin and 
norepinephrine, are the most intensely studied neurotransmitters in the central nervous system. 
Many antidepressants employ the use of selective serotonin re-uptake inhibitors (SSRIs) which 
increase the synaptic availability of serotonin. A well known SSRI is fluoxetine (Prozac®, 61).160 
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There are various drawbacks with the use of SSRIs, for example, lack of efficacy (30-40% non-
responders), requirement of almost three weeks for its full effect and many side effects such as 
nausea, anxiety, sleep disturbances and reduced appetite.161  
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 The antidepressants in current use have been developed as dual re-uptake inhibitors, a 
combination of serotonin and norepinephrine inhibition (SNRIs), for example Efexor® 
(venlafaxine, 62) and Cymbalta® (duloxetine, 63).162 While these newer medications are safer 
and easier to use, the previous issues of lack of efficacy and latency of onset, are still not fully 
resolved.  
 
MeO OH
N
Me
Me
O
N
S Me
H
(62) (63)  
 
  
 57
During the past decade, several therapeutic strategies have emerged to increase efficacy 
and accelerate the onset of antidepressant action compared to compounds in current use. One of 
the novel biogenic amine-based strategies is the “triple re-uptake” inhibitor which is also called 
the “broad spectrum” antidepressant as it is capable of simultaneously inhibiting the re-uptake of 
dopamine, serotonin and norepinephrine.163 The rationale for the design of the triple re-uptake 
inhibitor is that superior antidepressant effect can be achieved by the inclusion of a dopaminergic 
component to the norepinephrine and serotonin inhibitors.164, 165 There is numerous evidence that 
supports this hypothesis. Anhedonia, defined as an inability to experience pleasure and 
diminished interest in most activities, is a common depressive disorder, which has been 
associated with deficits in dopamine transmission.166,167 There is clinical evidence to indicate that 
co-administration of dopaminergic agents with the “standard” antidepressants, improves 
depressed moods in patients, including those individuals who were either resistant to or partially 
responsive to SNRIs alone.168 The improvement observed was in a significant proportion 
following the addition of these dopamine agonists. The hypothesis for the use of triple re-uptake 
inhibitors also states that it will act more rapidly than the several weeks of treatment required for 
conventional antidepressants. This is based on the evidence that chronic use of antidepressants 
produces a selective sensitization of dopamine receptors.166, 167 Since, dopaminergic neurons play 
a pivotal role in the control of motivation and reward-related behavior, the several of weeks of 
treatment required with conventional SNRIs may be to achieve stimulation of these neurons. 
Immediate increase in dopamine levels via inhibition of re-uptake of dopamine, may result in a 
more rapid treatment of symptoms associated with anhedonia than produced by SSRIs or SNRIs 
alone.  
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One of the triple re-uptake inhibitors which has been designed and has been studied 
extensively is DOV 216,303 which is an azabicyclo[3.1.0]hexane (64).169 Based on the structure 
of this compound, the design of a novel series of analogues was proposed which could also be 
developed as triple re-uptake inhibitors (65).  
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 Compounds 65 share several structural features with DOV 216,303. Figure 11 displays 
the overlay of geometry optimized structures 65e and 64. The azabicyclo ring system is a 
common feature in both the structures. The aryl substituent is attached to the 3-position on the 
nortropane ring which is analogous to the 3, 4-dichlorophenyl substituent on 1-position of 64. 
Further, both 64 and 65 possess the N-H group. The similarity of the structures of DOV 216,303 
and the target compounds, 65, suggests that the structure-activity relationships of this series of 
compounds (65) can provide leads with distinct pharmacological profiles for the treatment of 
depressive disorders. 
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                   DOV 216,303 (64)                                                    Tropene (65e)                                                       
 
 
Figure 11. Overlay of geometry optimized structures 64 and 65e. 
 
 
The retrosynthetic scheme for the synthesis of analogues of 65 is outlined in Scheme 14. 
The strategy for the development of these compounds utilizes the β-elimination of the tertiary 
alcohols (55) which were encountered previously while attempting to synthesize 3-aryl-3-
carbomethoxytropane analogues (43) and 3-aryl-3-propyltropane derivatives (51). 
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Scheme 14. Retrosynthetic route for the synthesis of 3-aryl-2-nortropene derivatives (65). 
  
 
The first step of the synthetic route for the synthesis of 3-aryl-2-nortropene analogues 
(65) was the protection of the tertiary amine (40) as a carbamate by employing 
ethylchloroformate to obtain the protected amine (54) as depicted in Scheme 15. Use of in situ 
generated organolithium reagents furnished the tertiary alcohols (55). Initial attempts to achieve 
the β-elimination and the cleavage of the carbamate in a single step to obtain the desired 
products (65) were unsuccesful. The conditions employed (HBr, AcOH) resulted in the the β-
elimination but removal of the carbamate group did not occur to give 66 as the only product.  
 
 61
N
O
N
O
O
O
EtO Cl
O
K2CO3, Tol, reflux, 20 h
N
O
O
OH
Br
n-BuLi, THF, -78oC, 4 h
89% 35-52%
(40) (54) (55)
R
R
(65)
HBr, AcOH
     18h
R = H, Cl, F, CF3, 3,4-Cl2
HBr, AcOH
     18h
(66)
NH
R
N
R
O
O
 
 
Scheme 15. Attempted synthesis of 3-aryl-2-nortropene derivatives (65). 
 
 
 
Therefore, the synthetic route was modified (Scheme 16) and milder conditions were employed 
to obtain the β-elimination products (66) which were then deprotected to afford the final 
products (65a-e) in 80-86% yields. 
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Scheme 16. Synthetic route for the synthesis of 3-aryl-2-nortropene derivatives (65). 
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2.6 Synthesis of Novel 3β-Aryl-3α-(4′, 4″-disubstituteddiphenylmethoxy)tropane 
Analogues-Future Directions. 
 Benztropine (8) is the parent compound of a leading class of dopamine uptake 
inhibitors.170-172 It is equipotent to cocaine and has displayed central nervous system stimulant 
activity in animal models.173-176 Benztropine, like meperidine (33), shares some structural 
features with cocaine and numerous phenyltropane analogues such as WIN 35,428 (5). The 
effects of various ortho, meta and para aromatic substitutions on the structure-activity 
relationships of benztropine at the dopamine transporter have been widely explored.177-180 It has 
been shown that these tropane derivatives bound with high affinity at the dopamine transporter 
and were selective at this transporter over other monoamine transporters such as serotonin and 
norepinephrine.  
 As discussed earlier, meperidine analogues 60 can act as inhibitors for the reuptake of 
serotonin and to some extent for the dopamine. A hybrid structure can be designed which 
incorporates the structural features of both the benztropine analogues as well as the meperidine 
derivatives to achieve a series of compounds that could exhibit affinity for both the dopamine 
and the serotonin transporters (Figure 12). Since cocaine has been found to display its 
reinforcing effects by binding to all three monoamine transporters, this series of ligands can 
provide leads for the development of novel medications for cocaine abuse. 
N
H3C
O
Benztropine (8) 3β-aryl-3α-arylmethoxytropane (60)
N CO2CH3
H3C
F
WIN 35,428 (5)
N
H3C
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            Figure 12. Hybrid structures of benztropine and tropane analogues 60. 
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Figure 13. Overlay of benztropine 67 and benzyl ether 60a. 
 
 
A simple and efficient synthetic route was designed for the synthesis of these unique 
tropane derivatives (67) which is presented in Scheme 17. The target compounds could be 
achieved from the reaction of benzhydryl chlorides with the tertiary alcohols (41). It has been 
previously demonstrated that these alcohols can be directly obtained from the commercially 
available 3-tropinone (40). 
 
N
H3CN
H3C
OH O
N
H3C
O
X
Y
Z
Z
X Y
Cl
Z-PhLi
(40)(41)(67)
 
 
 
Scheme 17. Retrosynthetic route for the synthesis of analogues of 67. 
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 The synthesis of the desired compounds, 67, is presented in Scheme 18. The 3β-aryl-3α-
hydroxytropanes (41) can be obtained from the commercially available 3-tropinone (40) by the 
action of in situ generated organolithium reagents. The reaction of chlorodiphenylmethane with 
the hydroxytropanes (41) was performed at 185oC in the absence of any solvent to yield the 
desired ligands. The analogue 67a was obtained in 35% yield by utilizing this synthetic strategy. 
 A series of novel compounds can be synthesized by following the synthetic route 
presented in Scheme 18 with variations in the substituents on the aromatic rings. Since these 
hybrid compounds contain the structural features of both the benztropines (DAT selective) and 
meperidine analogues (SERT selective), they could display equipotent binding affinities for both 
the dopamine and the serotonin transporters. Future investigations of these unique ligands can 
provide leads for the identification of novel medications for the treatment of cocaine addiction. 
 
N
H3C N
H3C
OHO
N
H3C
O
X
YBr
n-BuLi, THF, -78oC, 4 h
Z
Z
Z
Z = H, Cl, F, CF3, 3,4-Cl2
X Y
Cl
185oC
X, Y = H, Cl, F
(40) (41) (67)
N
H3C
O
Cl
(67a)  
Scheme 18. Synthetic route for the synthesis of analogues of 67. 
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CONCLUSION 
 
 A series of N-H and N-methyl 3β-aryl-3α-arylmethoxytropane analogues were 
synthesized and evaluated as dopamine and serotonin transporter ligands. The in vitro affinity 
(Ki) for the dopamine transporter and the serotonin transporter of this series was determined by 
inhibition of [3WIN]-35,428 and [3H]citalopram, respectively, in rat caudate putamen tissue. The 
results of this study clearly demonstrate that 3β-aryl-3α-arylmethoxytropane derivatives are 
selective ligands for the serotonin transporter over the dopamine transporter. The N-H analogues 
(59) were found to be more selective and potent than the N-methyl derivatives (60) for the 
serotonin transporter and the dopamine transporter. Most notably, the N-H derivatives, 3β-
phenyl-3α-(3”, 4”-dichlorophenyl)methoxy-8-azabicyclo[3.2.1]octane 59f and 3β-(4’-
chlorophenyl)-3α-(4”-chlorophenyl)methoxy-8-azabicyclo[3.2.1]octane 59l, exhibited the 
highest potency for the serotonin transporter reported to date for this class of compounds. They 
were found to be equipotent with paroxetine and fluoxetine, which are widely prescribed 
serotonin selective reuptake inhibitors for the treatment of depression. Also, 3β-(4’-
trifluoromethanephenyl)-3α-(4”-trifluoromethanephenyl)methoxy-8-azabicyclo[3.2.1]octane 59o 
was the found to be the most selective ligand for the serotonin transporter over the dopamine 
transporter in the series. Despite some structural similarities to the dopamine transporter 
selective 2-substituted-3β-phenyltropanes, these novel 3β-aryl-3α-arylmethoxy derivatives 
retained the inherent serotonin transporter selectivity of meperidine and exhibited more potent 
affinity for the serotonin transporter and were significantly less potent at the dopamine 
transporter than the corresponding 2-substituted-3β-aryltropanes. Overall, this investigation 
suggested that the chloro-substituted aryl rings at the 3-position of tropane is a key structural 
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feature for molecular recognition at the serotonin transporter as well as differentiation between 
the serotonin transporter and the dopamine transporter. 
 A new class of 8-azabicyclo[3.2.1]oct-2-ene derivatives (65a-e) has been synthesized 
based on the structure of triple reuptake inhibitor, DOV 216,303 which was developed for the 
treatment of depression. A short and efficient synthetic route has been developed for 
synthesizing the novel compounds 65. The final products were obtained from the tertiary 
alcohols (55a-e) in 64-72% overall yields.  
 A general method was designed for the preparation of a novel class of compounds as 
hybrids of benztropines and the benzyl ethers. These unique 3β-aryl-3α-(4’, 4”-
disubstituteddiphenylmethoxy)tropane analogues (67) could potentially exhibit affinity for both 
the dopamine and the serotonin transporters since they are hybrid structures of the dopamine 
transporter selective benztropines and the serotonin transporter selective meperidine derivatives 
60.  
 All the compounds synthesized in this study are in various stages of biological 
evaluation. The potency and efficacy that is determined for these compounds will provide the 
direction for further studies with these novel tropane derivatives. All the biological studies will 
be reported in due course. 
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EXPERIMENTAL SECTION 
 
 
All the chemicals were purchased form Aldrich Chemical Co., Milwaukee, WI, unless 
otherwise noted. Anhydrous THF was purchased from Mallindkrodt Baker. Anhydrous solvents 
toluene, dimethylformamide and acetonitrile were purchased from VWR International Co. and 
were used under argon without any further purification. Chromatography refers to column 
chromatography on silica gel (Silica Gel 60, 230-400 mesh). Reported melting points are 
uncorrected. NMR spectra were recorded on a Varian-Gemini 400 MHz spectrometer. Chemical 
shifts are reported in δ values with teteramethylsilane (TMS), employed as the internal standard. 
Elemental analyses were obtained from Atlantic Microlabs, Inc., Norcross, GA. 
 
 
General procedure A. Preparation of oxalate salts. 
 All the compounds were converted into the oxalate salts for biological testing, as well as 
for storage and handling purposes. The base (50-100mg) was dissolved in a minimum amount of 
THF (2-3 mL) and a saturated solution of oxalic acid (1.0 equiv.) in THF (5-7 mL) was added. 
The oxalate salts crystallized and were washed with THF (3 × 2mL) and purified by trituration 
with diethyl ether. Fractional moles of water could not be prevented, despite vigorous drying 
under vacuum (0.01 mmHg, overnight). All compounds were homogenous by thin-layer 
chromatography (CHCl3/CH3OH/NH4OH, 95:4.5:0.5). 
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General procedure B. Preparation of tertiary alcohols. 
 A solution of the appropriate arylbromide (2 eqiv.) in anhydrous THF (80 mL) was 
cooled to -78oC under an atmosphere of nitrogen. n-BuLi (2.5 M in hexanes, 2 eqiuv.) was added 
via syringe to the reaction flask and the mixture was stirred at -78oC for 2 h. Tropinone (40 or 
54) was dissolved in THF (20 mL) and added to the flask and the reaction mixture was stirred for 
another 2 h at -78oC. The reaction mixture was allowed to warm to room temperature and 
washed with 10% NH4Cl solution (50 mL). The aqueous layer was extracted with Et2O (3 × 25 
mL) and the solvent was removed under reduced pressure. 
Reduction of the unreacted tropinone. 
The residue was dissolved in CH3OH (100 mL). NaBH4 (1 equiv.) was added to the flask and the 
reaction mixture stirred at room temperature for 1 h. The reaction was quenched with 10% 
NH4Cl solution (50 mL) and concentrated under reduced pressure. The residue was partitioned 
between water and Et2O. The aqueous layer was extracted with Et2O (3 × 25 mL). The combined 
organic fractions were dried (Na2SO4) and the solvent removed under reduced pressure. The 
crude mixture obtained was purified by flash chromatography (Hexanes/EtOAc/CHCl3, 
80:10:10) to afford the tertiary alcohols 41 and 55. 
  
 
General procedure C. Preparation of methyl ethers (O-Alkylation). 
 A suspension of NaH (1.1 equiv.) in anhydrous DMF (10 mL) was prepared in a flask 
under the atmosphere of argon. Tertiary alcohol (55) was dissolved in DMF (10 mL) and added 
to the reaction flask at room temperature and the reaction mixture was stirred for 3 h (or till the 
evolution of hydrogen gas ceased). Dimethylsulphate (1.5 equiv.) was added via syringe to the 
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reaction flask and the mixture was stirred for another 2 h. Upon completion of the reaction, the 
reaction mixture was partitioned between water and Et2O. The aqueous layer was extracted with 
Et2O (3 × 30 mL). The combined organic fractions were dried (Na2SO4) and the solvent removed 
under reduced pressure. The crude product was purified by flash chromatography 
(Hexanes/EtOAc, 85:15) to afford the methoxy derivatives 56. 
 
 
General procedure D. Decarbonylation via LAH reduction. 
 A suspension of lithium aluminium hydride (5equiv.) was prepared in anhydrous THF 
(10 mL) and cooled to -78oC. The methoxytropane derivative (56) was dissolved in THF (10 
mL) and added to the reaction flask and the reaction mixture stirred at -78oC for 10-15 minutes 
and then allowed to stir at room temperature for 18 h. The reaction mixture was again cooled to -
78oC and quenched with Na2SO4•H2O. The mixture was then stirred at room temperature for 1 h. 
After LAH was completely quenched, the solids were filtered and washed with THF (5 × 30 
mL). The solvent was removed under reduced pressure. The residue was purified by flash 
chromatography (CHCl3/CH3OH/NH4OH, 90:9:1) to afford the N-Methyl derivatives 57. 
 
 
8-Ethoxycarbonyl-8-azabicyclo[3.2.1]-3-tropinone (54). 
 3-Tropinone (40, 20.0 g, 144 mmol) was dissolved in anhydrous toluene (150 mL). 
Potassium carbonate (993 mg, 7.18 mmol) and ethylchloroformate (68 mL, 718 mmol) were 
added to the solution and the reaction mixture was heated to reflux for 24 h. Upon completion of 
the reaction, solvent was removed from the reaction mixture under reduced pressure. The residue 
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was partitioned between water and CH2Cl2. Aqueous layer was extracted with CH2Cl2 (3 × 50 
mL). The combined organic fractions were dried (Na2SO4) and the solvent removed under 
reduced pressure. The crude product was purified by flash chromatography 
(Hexanes/Ethylacetate, 85:15) to afford the product, 54, as a colorless oil (22.4 g, 80%). 
1H-NMR (CDCl3): δ 4.56 (s, 2H), 4.20 (q, J = 7.4 Hz, 2H), 2.66 (s, 2H), 2.36 (d, J = 15.6 Hz, 
2H), 2.12-1.69 (m, 6H), 1.30 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ 206.2, 152.8, 60.1, 52.2, 
47.7, 28.3, 13.6.  
 
 
8-Ethoxycarbonyl-3β-phenyl-3α-hydroxy-8-azabicyclo[3.2.1]octane (55a). 
 General procedure B. This compound was obtained as a white solid (2.8 g, 40% yield). 
1H-NMR (CDCl3): δ 7.40 (d, J = 8.4 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.22 (t, J = 9.6 Hz, 1H), 
4.41 (s, 2H), 4.17 (q, J = 2.4 Hz, 2H), 2.45-1.69 (m, 8H), 1.27 (t, J = 6.8 Hz, 3H). 13C-NMR 
(CDCl3): δ 153.9, 149.8, 127.9, 126.4, 124.4, 73.0, 60.8, 53.3, 44.6, 28.0, 14.6. Anal. Calcd for 
C16H21NO3: C, 69.79, H, 7.69, N, 5.09. Found: C,  
 
 
8-Ethoxycarbonyl-3β-(4′-chlorophenyl)-3α-hydroxy-8-azabicyclo[3.2.1]octane (55b). 
General procedure B. This compound was obtained as a white solid (2.5 g, 32% yield). 
1H-NMR (CDCl3): δ 7.33-7.26 (m, 4H), 4.38 (s, 2H), 4.17 (q, J = 6.8 Hz, 2H), 2.30-1.73 (m, 
8H), 1.27 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ 154.2, 148.3, 132.8, 128.5, 126.1, 73.4, 61.2, 
53.4, 45.0, 28.3, 14.9. Anal. Calcd for C16H20ClNO3: C, 62.03, H, 6.51, N, 4.52. Found: C, 
62.03, H, 6.50, N, 4.43.  
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8-Ethoxycarbonyl-3β-(4′-fluorophenyl)-3α-hydroxy-8-azabicyclo[3.2.1]octane (55c). 
General procedure B. This compound was obtained as a white solid (4.7 g, 36% yield). 
1H-NMR (CDCl3): δ 7.37-7.33 (m, 2H), 7.02-6.97 (m, 2H), 4.39 (s, 2H), 4.17 (q, J = 6.8 Hz, 
2H), 2.30-1.82 (m, 8H), 1.27 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ 163.0, 154.2, 145.6, 
126.4, 115.2, 73.3, 61.2, 53.4, 44.6, 27.9, 14.9. Anal. Calcd for C16H20FNO3: C, 65.51, H, 6.87, 
N, 4.78. Found: C, 65.44, H, 6.95, N, 4.71.  
 
 
8-Ethoxycarbonyl-3β-(4′-trifluoromethanephenyl)-3α-hydroxy-8-azabicyclo[3.2.1]octane 
(55d). 
General procedure B. This compound was obtained as a white solid (2.6 g, 50% yield). 
1H-NMR (CDCl3): δ 7.58 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H),  4.43 (s, 2H), 4.19 (q, J = 
4.8 Hz, 2H), 2.45-1.82 (m, 8H), 1.29 (t, J = 6.8 Hz, 3H). 13C-NMR (CDCl3): δ 154.2, 153.6, 
125.4, 122.9, 119.2, 115.8, 73.7, 53.4, 45.1, 28.4, 14.9. Anal. Calcd for C17H20F3NO3: C, 59.47, 
H, 5.87, N, 4.08. Found: C, 59.24, H, 5.86, N, 4.06.  
 
 
8-Ethoxycarbonyl-3β-(3′, 4′-dichlorophenyl)-3α-hydroxy-8-azabicyclo[3.2.1]octane (55e). 
General procedure B. This compound was obtained as a colorless oil (3.0 g, 18% yield). 
1H-NMR (CDCl3): δ 7.51 (s, 1H), 7.38 (d, J = 8.4 Hz, 1H),  7.18 (d, J = 8.4 Hz, 1H),  4.39 (s, 
2H), 4.19 (q, J = 6.4 Hz, 2H), 2.28-1.80 (m, 8H), 1.28 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): 
δ 154.2, 150.3, 132.4, 130.8, 130.2, 127.1, 124.4, 73.1, 61.3, 53.4, 44.8, 28.3, 14.9. Anal. Calcd 
for C16H19Cl2NO3: C, 55.83, H, 5.56, N, 4.07. Found: C, 55.75, H, 5.59, N, 3.98.  
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3β-(4′-chlorophenyl)-3α-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane (41b). 
 General procedure B. This compound was purified by flash chromatography 
(CHCl3/CH3OH/NH4OH, 90:9:1). The compound was obtained as a white solid (2.3 g, 62% 
yield). 1H-NMR (DMSO): δ 7.46 (d, J = 8.8 Hz, 2H), 7.37 (d, J = 8.8 Hz, 2H),  4.82 (s, 2H), 3.33 
(s, 3H), 2.26-1.69 (m, 8H). 13C-NMR (DMSO): δ 150.9, 130.4, 127.5, 126.8, 71.1, 60.3, 44.9, 
40.1, 25.2.  
 
 
3β-(3′, 4′-dichlorophenyl)-3α-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane (41e). 
General procedure B. This compound was purified by flash chromatography 
(CHCl3/CH3OH/NH4OH, 90:9:1). The compound was obtained as a white solid (2.2 g, 35% 
yield). 1H-NMR (DMSO): δ 7.63 (s, 1H), 7.58 (d, J = 8.4 Hz, 1H),  7.39 (d, J = 8.4 Hz, 1H),  
4.99 (s, 2H), 3.36 (s, 3H), 2.25-1.70 (m, 8H). 13C-NMR (DMSO): δ 154.0, 131.3, 130.9, 129.3, 
128.0, 126.4, 71.9, 61.2, 45.7, 41.0, 26.1. 
 
 
8-Ethoxycarbonyl-3β-(4′-chlorophenyl)-3α-methoxy-8-azabicyclo[3.2.1]octane (56b). 
 General procedure C. This compound was obtained as orange oil. (0.8 g, 75% 
yield). 1H-NMR (CDCl3): δ 7.32-7.23 (m, 4H), 4.38 (s, 2H), 4.12 (q, J = 6.0 Hz, 2H), 2.9 (s, 3H), 
2.16-1.92 (m, 8H), 1.23 (t, J = 8.8 Hz, 3H). 13C-NMR (CDCl3): δ 153.8, 143.8, 132.9, 128.5, 
127.2, 77.5, 60.9, 52.9, 50.9, 401, 36.7, 28.3, 27.4, 14.8. 
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3β-(4′-chlorophenyl)-3α-methoxy-8-methyl-8-azabicyclo[3.2.1]octane (57b). 
General procedure D. This compound was obtained as colorless oil. (250 mg, 46% yield) 
and converted into an oxalate salt (General Procedure A) which was obtained as a white solid. 
1H-NMR (free base, CD3OD): δ 7.37-7.30 (m, 4H), 3.30 (s, 2H), 2.90 (s, 3H), 2.29 (s, 3H), 2.14-
2.00 (m, 8H). 13C-NMR (free base, CDCl3): δ 144.5, 132.7, 128.2, 127.4, 76.4, 60.8, 50.0, 38.9, 
24.9. Anal. Calcd for C15H20ClNO.HCl.H2O: C, 56.26, H, 7.24, N, 4.37. Found: C, 56.67, H, 
7.21, N, 4.35. 
 
 
3β-(3′, 4′-dichlorophenyl)-3α-methoxy-8-methyl-8-azabicyclo[3.2.1]octane (57e). 
General procedure D. This compound was obtained as colorless oil. (380 mg, 70% yield) 
and converted into an oxalate salt (General Procedure A) which was obtained as a white solid. 
1H-NMR (free base, CDCl3): δ 7.46 (s, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 8.8 Hz, 1H), 
3.19 (s, 2H), 2.92 (s, 3H), 2.30 (s, 3H), 2.08-1.96 (m, 8H). Anal. Calcd for C15H19Cl2NO.HCl: C, 
53.51, H, 5.99, N, 4.16. Found: C, 53.60, H, 6.03, N, 4.09. 
 
 
 
General procedure E. Preparation of benzyl ethers (O-Alkylation). 
 A suspension of NaH (1.1 equiv.) in anhydrous DMF (10 mL) was prepared in a flask 
under the atmosphere of argon. Tertiary alcohol (55a-e) was dissolved in DMF (10 mL) and 
added to the reaction flask at room temperature and the reaction mixture was stirred for 3 h (or 
till the evolution of hydrogen gas ceased). The appropriate benzyl halide (1 equiv.) was added 
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via syringe or dissolved in DMF (7-10 mL) and added to the reaction flask and the mixture was 
stirred for another 2 h. Upon completion of the reaction, the reaction mixture was partitioned 
between water and Et2O. The aqueous layer was extracted with Et2O (3 × 30 mL). The combined 
organic fractions were dried (Na2SO4) and the solvent removed under reduced pressure. The 
crude product was purified by flash chromatography (Hexanes/EtOAc, 85:15) to afford the 
benzyl ether derivatives 58a-q. 
 
 
8-Ethoxycarbonyl-3β-phenyl-3α-phenylmethoxy-8-azabicyclo[3.2.1]octane (58a). 
General procedure E. This compound was obtained as a light yellow oil (1.7 g, 90% 
yield). 1H-NMR (CDCl3): δ 7.40-7.23 (m, 10H), 4.43 (s, 2H), 4.14-4.08 (m, 4H), 2.35-1.93 (m, 
8H), 1.24 (t, J = 8.4 Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 145.4, 139.0, 128.6, 128.5, 127.5, 
127.4, 127.2, 125.8, 78.1, 65.4, 61.0, 53.5, 40.7, 37.3, 28.6, 14.9. 
 
 
8-Ethoxycarbonyl-3β-(4′-chlorophenyl)-3α-phenylmethoxy-8-azabicyclo[3.2.1]octane (58b). 
General procedure E. This compound was obtained as a light yellow oil (296 mg, 30% 
yield). 1H-NMR (CDCl3): δ 7.34-7.22 (m, 9H), 4.39 (s, 2H), 4.16-4.10 (m, 4H), 2.32-1.59 (m, 
8H), 1.24 (t, J = 6.8 Hz, 3H). 13C-NMR (CDCl3): δ  154.0, 144.0, 138.7, 133.4, 128.8, 128.6, 
127.5, 127.3, 127.2, 77.8, 65.5, 61.1, 53.3, 28.1, 14.9. 
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8-Ethoxycarbonyl-3β-(4′-fluorophenyl)-3α-phenylmethoxy-8-azabicyclo[3.2.1]octane (58c). 
General procedure E. This compound was obtained as a light yellow oil (390 mg, 40% 
yield). 1H-NMR (CDCl3): δ 7.37-6.98 (m, 9H), 4.39 (s, 2H), 4.13-4.10 (m, 4H), 2.34-1.93 (m, 
8H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  163.3, 160.9, 153.9, 141.3, 138.8, 128.5, 
127.6, 127.5, 127.5, 115.5, 77.7, 65.4, 61.1, 53.3, 40.8, 37.4, 27.8, 14.9. 
 
 
8-Ethoxycarbonyl-3β-(4′-trifluoromethanephenyl)-3α-phenylmethoxy-8-azabicyclo 
[3.2.1]octane (58d). 
General procedure E. This compound was obtained as a light yellow oil (780 mg, 82.3% 
yield). 1H-NMR (CDCl3): δ 7.60-7.23 (m, 9H), 4.41 (s, 2H), 4.16-4.11 (m, 4H), 2.34-1.97 (m, 
8H), 1.25 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 149.5, 138.5, 129.9, 128.6, 127.2, 
126.2, 125.7, 78.1, 65.7, 61.1, 53.3, 40.7, 37.1, 28.6, 14.9. 
 
 
8-Ethoxycarbonyl-3β-(3′,4′-dichlorophenyl)-3α-phenylmethoxy-8-azabicyclo[3.2.1]octane 
(58e). 
General procedure E. This compound was obtained as a light yellow oil (815 mg, 72% 
yield). 1H-NMR (CDCl3): δ 7.47-7.22 (m, 8H), 4.40 (s, 2H), 4.16-4.11 (m, 4H), 2.31-1.94 (m, 
8H), 1.26 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 145.9, 138.3, 132.8, 131.6, 130.6, 
128.6, 128.1, 127.6, 127.3, 125.4, 77.6, 65.7, 61.1, 53.0, 40.6, 37.1, 28.5, 14.9. 
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8-Ethoxycarbonyl-3β-phenyl-3α-(3″, 4″-dichlorophenyl)methoxy-8-azabicyclo[3.2.1]octane 
(58f). 
General procedure E. This compound was obtained as a light yellow oil (380 mg, 24% 
yield). 1H-NMR (CDCl3): δ 7.37-7.03 (m, 8H), 4.43 (s, 2H), 4.13 (q, J = 7.2 Hz, 2H), 4.02 (s, 
2H), 2.34-1.97 (m, 8H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 144.8, 139.3, 
132.6, 130.4, 128.7, 127.8, 126.4, 125.7, 78.4, 64.1, 61.1, 53.3, 37.4, 28.2, 14.9. 
 
 
8-Ethoxycarbonyl-3β -(4′-chlorophenyl)-3α -(3″,4″-dichlorophenyl)methoxy-8-azabicyclo 
[3.2.1] octane (58g). 
General procedure E. This compound was obtained as a light yellow oil (796 mg, 62% 
yield). 1H-NMR (CDCl3): δ 7.38-7.02 (m, 7H), 4.40 (s, 2H), 4.13 (q, J = 6.8 Hz, 2H), 4.04 (s, 
2H), 2.30-1.97 (m, 8H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 143.8, 138.9, 
133.6, 132.5, 131.3, 130.5, 128.9, 128.8, 127.1, 126.3, 78.0, 64.1, 61.1, 53.0, 40.5, 37.0, 28.5, 
14.9. 
 
 
8-Ethoxycarbonyl-3β -(4′-fluorophenyl)-3α -(3″,4″-dichlorophenyl)methoxy-8-azabicyclo 
[3.2.1]octane (58h). 
General procedure E. This compound was obtained as a light yellow oil (230 mg, 20% 
yield). 1H-NMR (CDCl3): δ 7.38-6.99 (m, 7H), 4.39 (s, 2H), 4.12 (q, J = 7.2 Hz, 2H), 4.05 (s, 
2H), 2.32-1.96 (m, 8H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  163.4, 153.9, 140.7, 
139.0, 130.5, 128.9, 127.4, 126.3, 115.6, 77.9, 64.1, 61.2, 53.2, 40.7, 37.4, 28.6, 14.9. 
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8–Ethoxycarbonyl-3β-(4′-trifluoromethane phenyl)-3α -(3″, 4″-dichlorophenyl) methoxy – 
8 – azabicyclo [3.2.1] octane (58i). 
General procedure E. This compound was obtained as a light yellow oil (687 mg, 55% 
yield). 1H-NMR (CDCl3): δ 7.61-7.03 (m, 7H), 4.42 (s, 2H), 4.16 (q, J = 7.2 Hz, 2H), 4.07 (s, 
2H), 2.33-1.97 (m, 8H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 148.8, 138.7, 
130.5, 128.9, 126.3, 126.1, 125.8, 78.3, 64.4, 61.2, 52.9, 40.6, 37.0, 28.6, 27.6, 14.9. 
 
 
8–Ethoxycarbonyl- 3β-(3′, 4′-dichlorophenyl)-3α -(3″, 4″- dichlorophenyl) methoxy–8– aza 
bicyclo[3.2.1] octane (58j). 
General procedure E. This compound was obtained as a light yellow oil (850 mg, 57% 
yield). 1H-NMR (CDCl3): δ 7.41-7.02 (m, 6H), 4.43 (s, 2H), 4.12 (q, J = 6.8 Hz, 2H), 4.02 (s, 
2H), 2.28-1.98 (m, 8H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 145.3, 138.6, 
133.0, 132.7, 131.9, 131.6, 130.8, 130.6, 129.1, 128.0, 126.4, 125.2, 77.9, 64.5, 61.2, 53.1, 40.6, 
37.1, 28.6, 27.7, 14.9. 
 
 
8–Ethoxycarbonyl-3β-phenyl-3α -(4″-chlorophenyl)methoxy–8–azabicyclo[3.2.1]octane 
(58k). 
General procedure E. This compound was obtained as a light yellow oil (300 mg, 40% 
yield). 1H-NMR (CDCl3): δ 7.38-7.15 (m, 9H), 4.39 (s, 2H), 4.12 (q, J = 7.2 Hz, 2H), 4.06 (s, 
2H), 2.33-1.95 (m, 8H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 144.0, 133.0, 
131.2, 129.7, 128.7, 128.6, 128.6, 127.7, 127.2, 125.8, 124.5, 77.43, 64.7, 61.1, 53.5, 27.9, 14.9. 
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8–Ethoxycarbonyl-3β -(4′-chlorophenyl)-3α -(4″-chlorophenyl)methoxy–8–azabicyclo 
[3.2.1] octane (58l). 
General procedure E. This compound was obtained as a light yellow oil (616 mg, 40% 
yield). 1H-NMR (CDCl3): δ 7.32-7.15 (m, 8H), 4.42 (s, 2H), 4.13 (q, J = 7.2 Hz, 2H), 4.02 (s, 
2H), 2.29-1.93 (m, 8H), 1.25 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  154.0, 143.8, 137.2, 
135.5, 133.6, 133.3, 128.8, 128.7, 128.6, 128.5, 127.3, 126.1, 77.9, 64.8, 61.2, 53.3, 40.7, 37.2, 
28.6, 27.7, 14.9. 
 
 
8–Ethoxycarbonyl-3β -(4′-trifluoromethanephenyl)-3α -(4″-chlorophenyl)methoxy–8–aza 
bicyclo[3.2.1] octane (58m). 
General procedure E. This compound was obtained as a light yellow oil (1.0 g, 56% 
yield). 1H-NMR (CDCl3): δ 7.60 (d, J = 8.8 Hz, 2H),  7.49 (d, J = 8.0 Hz, 2H),  7.30 (d, J = 8.0 
Hz, 2H),  7.18 (d, J = 8.0 Hz, 2H),  4.45 (s, 2H), 4.13 (q, J = 7.2 Hz, 2H), 4.04 (s, 2H), 2.32-1.95 
(m, 8H), 1.25 (t, J = 6.8 Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 149.1, 136.8, 133.3, 130.0, 129.7, 
128.7, 126.1, 125.7, 78.2, 64.9, 61.1, 53.2, 40.7, 37.0, 28.6, 14.8.  
 
 
8–Ethoxycarbonyl-3β -(4′-fluorophenyl)-3α -(4″-fluorophenyl)methoxy–8–azabicyclo 
[3.2.1] octane (58n). 
General procedure E. This compound was obtained as a light yellow oil (493 mg, 30% 
yield). 1H-NMR (CDCl3): δ 7.36-6.97 (m, 8H), 4.38 (s, 2H), 4.11 (q, J = 6.8 Hz, 2H), 4.04 (s, 
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2H), 2.32-1.94 (m, 8H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  163.5, 161.1, 153.9, 
141,1, 134.5, 128.9, 127.6, 115,5, 77.7, 64.7, 61.1, 53.2, 40.7, 37.3, 28.5, 14.9.  
 
 
8–Ethoxycarbonyl-3β -(4′-trifluoromethanephenyl)-3α -(4″-trifluoromethanephenyl) 
methoxy –8–azabicyclo[3.2.1]octane (58o). 
General procedure E. This compound was obtained as a light yellow oil (955 mg, 60% 
yield). 1H-NMR (CDCl3): δ 7.58 (t, J = 5.2 Hz, 4H), 7.50 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 
Hz, 2H), 4.46 (s, 2H), 4.21 (s, 2H), 4.15 (q, J = 7.2 Hz, 2H), 2.35-1.97 (m, 8H), 1.25 (t, J = 6.8 
Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 148.9, 142.5, 129.8, 127.2, 125.7, 125.5, 122.9, 78.3, 
65.0, 61.2, 53.2, 40.7, 37.2, 28.6, 14.9.  
 
 
8–Ethoxycarbonyl-3β-(4′-chlorophenyl)-3α -(4″-trifluoromethanephenyl)methoxy–8–aza 
bicyclo[3.2.1] octane (58p). 
General procedure E. This compound was obtained as a light yellow oil (683 mg, 57% 
yield). 1H-NMR (CDCl3): δ 7.58-7.25 (m, 8H), 4.44 (s, 2H), 4.18 (s, 2H), 4.14 (q, J = 7.2 Hz, 
2H), 2.32-1.95 (m, 8H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ  153.9, 143.5, 142.7, 
133.6, 128.8, 127.1, 125.5, 125.4, 78.0, 64.7, 61.1, 53.2, 40.6, 37.2, 28.6, 14.8.  
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8–Ethoxycarbonyl-3β-(3′, 4′-dichlorophenyl)-3α -(4″-trifluoromethane phenyl)methoxy– 8 
–azabicyclo[3.2.1]octane (58q). 
General procedure E. This compound was obtained as a light yellow oil (690 mg, 47% 
yield). 1H-NMR (CDCl3): δ 7.60 (d, J = 8.4 Hz, 2H), 7.44-7.34 (m, 3H), 7.21 (d, J = 8.4 Hz, 2H), 
4.41 (s, 2H), 4.16-4.11 (m, 4H), 2.32-1.96 (m, 8H), 1.25 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): 
δ  153.9, 145.3, 142.4, 132.9, 130.7, 128.0, 125.6, 125,5, 125.2, 77.8, 64.9, 61.2, 53.0, 40.5, 37.0, 
28.5, 14.8.  
 
 
 
General procedure F. Decarbonylation via hydrazine hydrate/KOH. 
 The benzylether derivative (58a-q) or the 8-azabicyclo[3.2.1]oct-2-ene derivative (66a-e) 
was dissolved in ethyleneglycol (20-30 mL). Potassium hydroxide (26 equiv.) and hydrazine 
hydrate (5 equiv.) were added to the flask and the mixture was heated at reflux for 3 h. Upon 
cooling to room temperature, the reaction mixture was partitioned between water and Et2O. The 
aqueous layer was extracted with Et2O (3 × 30 mL). The combined organic fractions were dried 
(Na2SO4) and the solvent was removed under reduced pressure. The crude product was purified 
by flash chromatography (CHCl3/CH3OH/NH4OH, 90:9:1) to afford the N-H benzylether 
derivatives 59a-q or N-H 3-aryl-2-nortropene derivatives 65a-e. 
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3β-Phenyl-3α−phenylmethoxy-8–azabicyclo[3.2.1]nortropane (59a). 
 General procedure F. This compound was obtained as a light yellow oil (660 mg, 
55% yield) and converted into an oxalate salt (General Procedure A) which was obtained as a 
white solid. 1H-NMR (free base, CDCl3): δ 7.40-7.17 (m, 10H), 4.06 (s, 2H), 3.70 (s, 2H), 2.36-
1.80 (m, 8H). Anal. Calcd for C20H23NO•HCl•0.25H2O: C, 71.84; H, 7.39; N, 4.19. Found: C, 
71.58; H, 7.37; N, 4.18. 
 
 
3β-(4′-Chlorophenyl)-3α−phenylmethoxy-8–azabicyclo[3.2.1]nortropane (59b). 
 General procedure F. This compound was obtained as a light yellow oil (226 mg, 
90% yield) and converted into an oxalate salt (General Procedure A) which was obtained as a 
white solid. 1H-NMR (free base, CDCl3): δ 7.36-7.21 (m, 9H), 4.09 (s, 2H), 3.73 (s, 2H), 2.34-
1.79 (m, 8H). Anal. Calcd for C20H22ClNO•C2H2O4: C, 63.23; H, 5.79; N, 3.35. Found: C, 
63.08; H, 5.67; N, 3.32. 
 
 
3β-(4′-Fluorophenyl)-3α−phenylmethoxy-8–azabicyclo[3.2.1]nortropane (59c). 
General procedure F. This compound was obtained as a light yellow oil (261 mg, 87% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.40-6.97 (m, 9H), 4.07 (s, 2H), 3.66 (s, 2H), 2.35-1.77 (m, 
8H). Anal. Calcd for C20H22FNO•C2H2O4•0.5H2O: C, 64.38; H, 6.14; N, 3.41. Found: C, 64.09; 
H, 6.13; N, 3.49. 
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3β-(4′-Trifluoromethanephenyl)-3α−phenylmethoxy-8–azabicyclo[3.2.1]nortropane (59d). 
General procedure F. This compound was obtained as a light yellow oil (418 mg, 69% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.55 (q, J = 8.4 Hz, 4H), 7.35-7.25 (m, 5H), 4.10 (s, 2H), 
3.67 (s, 2H), 2.35-1.78 (m, 8H). Anal. Calcd for C21H22F3NO•C2H2O4: C, 61.19; H, 5.36; N, 
3.10. Found: C, 61.32; H, 5.55; N, 3.15. 
 
 
3β-(3′, 4′-Dichlorophenyl)-3α−phenylmethoxy-8–azabicyclo[3.2.1]nortropane (59e). 
General procedure F. This compound was obtained as a light yellow oil (590 mg, 92% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.51-7.24 (m, 8H), 4.09 (s, 2H), 3.67 (s, 2H), 2.31-1.77 (m, 
8H). Anal. Calcd for C20H21Cl2NO•C2H2O4: C, 58.42; H, 5.13; N, 3.10. Found: C, 58.16; H, 
5.21; N, 3.05. 
 
 
3β-Phenyl-3α−(3″, 4″-dichlorophenyl)methoxy-8–azabicyclo[3.2.1]nortropane (59f). 
General procedure F. This compound was obtained as a light yellow oil (212 mg, 85% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.39-7.05 (m, 8H), 4.04 (s, 2H), 3.73 (s, 2H), 2.42-1.86 (m, 
8H). Anal. Calcd for C20H21Cl2NO•C2H2O4•0.5H2O: C, 57.28; H, 5.24; N, 3.04. Found: C, 
57.32; H, 5.13; N, 3.07. 
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3β-(4′-Chlorophenyl)-3α−(3″, 4″-dichlorophenyl)methoxy-8–aza[3.2.1]nortropane (59g). 
General procedure F. This compound was obtained as a light yellow oil (591 mg, 93% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.38-7.04 (m, 7H), 4.02 (s, 2H), 3.68 (s, 2H), 2.31-1.78 (m, 
8H). Anal. Calcd for C20H20Cl3NO•C2H2O4: C, 54.28; H, 4.56; N, 2.88. Found: C, 54.26; H, 
4.63; N, 2.81. 
 
 
3β-(4′-Fluorophenyl)-3α−(3″, 4″-dichlorophenyl)methoxy-8–aza[3.2.1]-nortropane (59h). 
General procedure F. This compound was obtained as a light yellow oil (162 mg, 90% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.38-7.32 (m, 4H), 7.06-6.98 (m, 3H), 4.02 (s, 2H), 3.70 (s, 
2H), 2.34-1.81 (m, 8H). Anal. Calcd for C20H20Cl2FNO•C2H2O4.H2O: C, 54.11; H, 4.95; N, 2.87. 
Found: C, 53.92; H, 4.77; N, 2.71. 
 
 
 
3β-(4′-Trifluoromethanephenyl)-3α− (3″, 4″-dichlorophenyl)methoxy-8–azabicyclo[3.2.1] 
nortropane (59i). 
General procedure F. This compound was obtained as a light yellow oil (498 mg, 92.5% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.59 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 7.37 (t, J 
= 8.0 Hz, 2H), 7.07 (d, J = 8.4 Hz, 1H), 4.04 (s, 2H), 3.72 (s, 2H), 2.34-1.81 (m, 8H). Anal. 
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Calcd for C21H20Cl2F3NO•C2H2O4•0.5H2O: C, 52.19; H, 4.38; N, 2.65. Found: C, 52.50; H, 
4.37; N, 2.73. 
 
 
3β-(3′,4′-Dichlorophenyl)-3α−(3″,4″-dichlorophenyl)methoxy-8–azabicyclo[3.2.1] 
nortropane (59j). 
General procedure F. This compound was obtained as a light yellow oil (620 mg, 88% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.46-7.34 (m, 4H), 7.22 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 8.4 
Hz, 1H), 4.04 (s, 2H), 3.70 (s, 2H), 2.30-1.79 (m, 8H). Anal. Calcd for C20H19Cl4NO•C2H2O4: C, 
50.70; H, 4.06; N, 2.69. Found: C, 50.71; H, 4.12; N, 2.76. 
 
 
3β-Phenyl-3α−(4″-chlorophenyl)methoxy-8–azabicyclo[3.2.1]nortropane (59k). 
General procedure F. This compound was obtained as a light yellow oil (209 mg, 85% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.40-7.17 (m, 9H), 4.06 (s, 2H), 3.70 (s, 2H), 2.36-1.80 (m, 
8H). Anal. Calcd for C20H22ClNO•C2H2O4: C, 63.23; H, 5.79; N, 3.35. Found: C, 62.95; H, 5.81; 
N, 3.32. 
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3β-(4′-Chlorophenyl)-3α−(4″-chlorophenyl)methoxy-8–azabicyclo[3.2.1]nortropane (59l). 
General procedure F. This compound was obtained as a light yellow oil (143 mg, 70% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.32-7.16 (m, 8H), 4.04 (s, 2H), 3.69 (s, 2H), 2.28-1.79 (m, 
8H). Anal. Calcd for C20H21Cl2NO•C2H2O4: C, 58.42; H, 5.13; N, 3.10. Found: C, 58.33; H, 
5.12; N, 3.12. 
 
 
3β-(4′-Trifluoromethanephenyl)-3α− (4″-chlorophenyl)methoxy-8–azabicyclo[3.2.1] 
nortropane (59m). 
General procedure F. This compound was obtained as a light yellow oil (390 mg, 46% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.59 (d, J = 8.8 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 7.30 (d, J 
= 8.0 Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H), 4.06 (s, 2H), 3.70 (s, 2H), 2.34-1.79 (m, 8H). Anal. 
Calcd for C21H21ClF3NO•HCl•0.75H2O: C, 53.86; H, 5.60; N, 2.99. Found: C, 54.06; H, 5.53; 
N, 2.97. 
 
 
3β- (4′-Fluorophenyl)- 3α− (4″-fluorophenyl) methoxy-8–azabicyclo[3.2.1]nortropane 
(59n). 
General procedure F. This compound was obtained as a light yellow oil (366 mg, 97% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.38-7.35 (m, 2H), 7.20-7.17 (m, 2H), 7.02-6.97 (m, 4H), 
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4.02 (s, 2H), 3.67 (s, 2H), 2.34-1.78 (m, 8H). Anal. Calcd for C20H21F2NO•C2H2O4•0.25H2O: C, 
62.33; H, 5.59; N, 3.39. Found: C, 62.34; H, 5.75; N, 3.35. 
 
 
3β-(4′-Trifluoromethanephenyl)-3α− (4″-trifluoromethanephenyl)methoxy-8–azabicyclo 
[3.2.1]nortropane (59o). 
General procedure F. This compound was obtained as a light yellow oil (610 mg, 85% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.59-7.51 (m, 6H), 7.39 (d, J = 8.0 Hz, 2H), 4.16 (s, 2H), 
3.75 (s, 2H), 2.37-1.84 (m, 8H). Anal. Calcd for C22H21F6NO•C2H2O4•H2O: C, 53.63; H, 4.69; 
N, 2.61. Found: C, 53.46; H, 4.77; N, 2.78. 
 
 
3β-(4′-Chlorophenyl)-3α−(4″-trifluoromethanephenyl)methoxy-8–azabicyclo 
[3.2.1]nortropane (59p). 
General procedure F. This compound was obtained as a light yellow oil (436 mg, 81% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.58-7.26 (m, 8H), 4.13 (s, 2H), 3.68 (s, 2H), 2.34-1.78 (m, 
8H).  
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3β -(3′, 4′-Dichlorophenyl)-3α−(4″-trifluoromethanephenyl)methoxy-8–azabicyclo[3.2.1] 
nortropane (59q). 
General procedure F. This compound was obtained as a light yellow oil (472 mg, 85% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.60 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 2.4 Hz, 2H), 7.37 (t, J 
= 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz, 1H), 4.14 (s, 2H), 3.68 (s, 2H), 2.32-1.78 (m, 8H). Anal. 
Calcd for C21H20Cl2F3NO•C2H2O4: C, 53.09; H, 4.26; N, 2.69. Found: C, 53.09; H, 4.42; N, 
2.80. 
 
 
 
General procedure G. N-Methylation of secondary amines. 
 The secondary amine (59a-q) was dissolved in CH3CN (7-10 mL) and 37% aqueous 
formaldehyde solution (5 equiv.) was added to it followed by sodium cyanoborohydride (1.5 
equiv.). The reaction mixture was stirred for 10 minutes, and then glacial acetic acid was added 
dropwise until the solution became neutral. The reaction mixture was stirred at room temperature 
for another 1 h. A saturated solution of NaHCO3 was added to basify the mixture and the solvent 
was removed under reduced pressure. The residue was partitioned between water and Et2O. 
Aqueous layer was extracted with Et2O (3 × 20 mL). The combined organic fractions were dried 
(Na2SO4) and the solvent removed under reduced pressure. The crude product was purified by 
flash chromatography (CHCl3/CH3OH/NH4OH, 96:3.5:0.5) to afford the N-methyl benzylether 
derivatives 60a-q. 
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3β-Phenyl-3α−phenylmethoxy-8-methyl-8–azabicyclo[3.2.1]octane (60a). 
General procedure G. This compound was obtained as a light yellow oil (515 mg, 82% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.44-7.22 (m, 10H), 4.10 (s, 2H), 3.25 (s, 2H), 2.35 (s, 3H), 
2.32-1.98 (m, 8H). Anal. Calcd for C22H21F6NO•C2H2O4•H2O: C, 53.63; H, 4.69; N, 2.61. 
Found: C, 53.46; H, 4.77; N, 2.78. 
 
 
3β-(4′-Chlorophenyl)-3α−phenylmethoxy-8-methyl -8–azabicyclo[3.2.1]octane (60b). 
General procedure G. This compound was obtained as a light yellow oil (159 mg, 79% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.39-7.24 (m, 9H), 4.10 (s, 2H), 3.32 (s, 2H), 2.39 (s, 3H), 
2.34-2.02 (m, 8H). Anal. Calcd for C21H24ClNO•C2H2O4•0.25H2O: C, 63.30; H, 6.12; N, 3.21. 
Found: C, 63.02; H, 6.20; N, 3.25. 
 
 
3β-(4′-Fluorophenyl)-3α−phenylmethoxy-8-methyl-8–azabicyclo[3.2.1]octane (60c). 
General procedure G. This compound was obtained as a light yellow oil (80 mg, 50% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.45-6.98 (m, 9H), 4.11 (s, 2H), 3.44 (s, 2H), 2.48 (s, 3H), 
2.33-2.08 (m, 8H). Anal. Calcd for C21H24FNO•C2H2O4: C, 66.49; H, 6.31; N, 3.37. Found: C, 
66.19; H, 6.39; N, 3.38. 
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3β-(4′-Trifluoromethanephenyl)-3α−phenylmethoxy-8-methy-8–azabicyclo[3.2.1]octane 
(60d). 
General procedure G. This compound was obtained as a light yellow oil (214 mg, 84% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.56-7.26 (m, 9H), 4.11 (s, 2H), 3.29 (s, 2H), 2.36 (s, 3H), 
2.28-2.02 (m, 8H). Anal. Calcd for C22H24F3NO•C2H2O4: C, 61.93; H, 5.63; N, 3.01. Found: C, 
62.04; H, 5.67; N, 2.98. 
 
 
3β-(3′, 4′-Dichlorophenyl)-3α−phenylmethoxy-8-methyl-8–azabicyclo[3.2.1]octane (60e). 
General procedure G. This compound was obtained as a light yellow oil (340 mg, 87% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.53-7.24 (m, 8H), 4.10 (s, 2H), 3.30 (s, 2H), 2.36 (s, 3H), 
2.31-2.01 (m, 8H). Anal. Calcd for C21H23Cl2NO•C2H2O4: C, 59.24; H, 5.40; N, 3.00. Found: C, 
59.00; H, 5.47; N, 2.97. 
 
 
3β-Phenyl-3α−(3″, 4″-dichlorophenyl)methoxy-8-methyl-8–azabicyclo[3.2.1]octane (60f). 
General procedure G. This compound was obtained as a light yellow oil (149 mg, 82% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.42-7.08 (m, 8H), 4.06 (s, 2H), 3.39 (s, 2H), 2.44 (s, 3H), 
2.29-2.04 (m, 8H). Anal. Calcd for C21H23Cl2NO•C2H2O4: C, 59.24; H, 5.40; N, 3.00. Found: C, 
59.05; H, 5.60; N, 2.98. 
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3β- (4′-Chlorophenyl)-3α− (3″, 4″-dichlorophenyl)methoxy-8-methyl-8–azabicyclo [3.2.1] 
octane (60g). 
General procedure G. This compound was obtained as a light yellow oil (360 mg, 90% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.38-7.04 (m, 7H), 4.02 (s, 2H), 3.30 (s, 2H), 2.35 (s, 3H), 
2.27-2.02 (m, 8H). Anal. Calcd for C21H22Cl3NO•C2H2O4: C, 55.16; H, 4.83; N, 2.80. Found: C, 
55.31; H, 4.85; N, 2.80. 
 
 
3β-(4′-Fluorophenyl)-3α−(3″, 4″-dichlorophenyl)methoxy-8-methyl-8–azabicyclo [3.2.1] 
octane (60h). 
General procedure G. This compound was obtained as a light yellow oil (74 mg, 79% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.43-7.35 (m, 4H), 7.06-7.00 (m, 3H), 4.08 (s, 2H), 3.56 (s, 
2H), 2.57 (s, 3H), 2.34-2.14 (m, 8H). Anal. Calcd for C21H22Cl2FNO•C2H2O4: C, 57.04; H, 4.99; 
N, 2.89. Found: C, 56.81; H, 5.15; N, 2.78. 
 
 
3β -(4′-Trifluoromethanephenyl)-3α − (3″,4″-dichlorophenyl)methoxy-8-methyl-8-
azabicyclo[3.2.1]octane (60i). 
General procedure G. This compound was obtained as a light yellow oil (316 mg, 84% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.59 (d, J = 8.0 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H), 7.38 (t, J 
 93
= 8.0 Hz, 2H), 7.07 (d, J = 8.4 Hz, 1H), 4.06 (s, 2H), 3.38 (s, 2H), 2.38 (s, 3H), 2.33-2.04 (m, 
8H). Anal. Calcd for C22H22Cl2F3NO•C2H2O4: C, 53.95; H, 4.53; N, 2.62. Found: C, 53.77; H, 
4.54; N, 2.66. 
 
 
3β-(3′, 4′-Dichlorophenyl) -3α− (3″, 4″-dichlorophenyl)methoxy-8- methyl-8–azabicyclo 
[3.2.1]octane (60j). 
General procedure G. This compound was obtained as a light yellow oil (366 mg, 67% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.48 (d, J = 2.4 Hz, 1H), 7.40 (s, 1H), 7.38 (s, 1H), 7.35 (s, 
1H), 7.25 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 8.0 Hz, 1H), 4.05 (s, 2H), 3.35 (s, 2H), 2.39 (s, 3H), 
2.36-2.01 (m, 8H). Anal. Calcd for C21H21Cl4NO•C2H2O4•0.75H2O: C, 50.34; H, 4.50; N, 2.55. 
Found: C, 50.43; H, 4.57; N, 2.57. 
 
 
3β-Phenyl-3α−(4″-chlorophenyl)methoxy-8-methyl-8–azabicyclo[3.2.1]octane (60k). 
General procedure G. This compound was obtained as a light yellow oil (144 mg, 84% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.44-7.18 (m, 9H), 4.08 (s, 2H), 3.41 (s, 2H), 2.46 (s, 3H), 
2.31-2.05 (m, 8H). Anal. Calcd for C21H24ClNO•C2H2O4: C, 63.96; H, 6.07; N, 3.24. Found: C, 
64.21; H, 5.98; N, 3.20. 
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3β-(4′-Chlorophenyl)-3α−(4″-chlorophenyl)methoxy-8-methyl-8–azabicyclo[3.2.1]octane 
(60l). 
General procedure G. This compound was obtained as a light yellow oil (129 mg, 79% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.34-7.16 (m, 8H), 4.03 (s, 2H), 3.26 (s, 2H), 2.34 (s, 3H), 
2.25-2.02 (m, 8H). Anal. Calcd for C21H23Cl2NO•HCl•H2O: C, 58.55; H, 6.08; N, 3.25. Found: 
C, 58.53; H, 6.19; N, 3.28. 
 
 
3β-(4′-Trifluoromethanephenyl)-3α−(4″-chlorophenyl)methoxy-8-methyl-8–
azabicyclo[3.2.1]octane (60m). 
General procedure G. This compound was obtained as a light yellow oil (117 mg, 60% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.56 (q, J = 8.8 Hz, 4H), 7.31 (d, J = 8.4 Hz, 2H), 7.20 (d, J 
= 8.4 Hz, 2H), 4.07 (s, 2H), 3.33 (s, 2H), 2.39 (s, 3H), 2.27-2.03 (m, 8H). Anal. Calcd for 
C22H23ClNO•HCl•0.75H2O: C, 57.46; H, 5.59; N, 3.05. Found: C, 57.22; H, 5.54; N, 3.09. 
 
 
3β-(4′-Fluorophenyl)-3α−(4″-fluorophenyl)methoxy-8-methyl-8–azabicyclo[3.2.1]octane 
(60n). 
General procedure G. This compound was obtained as a light yellow oil (152 mg, 68% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.42-7.38 (m, 2H), 7.21-7.02 (m, 2H), 7.00 (t, J = 8.4 Hz, 
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4H), 4.05 (s, 2H), 3.38 (s, 2H), 2.43 (s, 3H), 2.29-2.04 (m, 8H). Anal. Calcd for 
C21H23F2NO•C2H2O4: C, 63.73; H, 5.81; N, 3.27. Found: C, 63.52; H, 5.82; N, 3.27. 
 
 
3β-(4′-Trifluoromethanephenyl)-3α−(4″-trifluoromethanephenyl)methoxy-8-methyl-8–
azabicyclo[3.2.1]octane (60o). 
General procedure G. This compound was obtained as a light yellow oil (340 mg, 70% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.60-7.51 (m, 6H), 7.39 (d, J = 7.6 Hz, 2H), 4.16 (s, 2H), 
3.30 (s, 2H), 2.36 (s, 3H), 2.31-2.03 (m, 8H). Anal. Calcd for C23H23F6NO•C2H2O4•0.5H2O: C, 
55.35; H, 4.83; N, 2.58. Found: C, 55.36; H, 4.93; N, 2.66. 
 
 
3β -(4′-Chlorophenyl)-3α − (4″-trifluoromethanephenyl)methoxy-8-methyl-8–azabicyclo 
[3.2.1]octane (60p). 
General procedure G. This compound was obtained as a light yellow oil (307 mg, 95% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.58 (d, J = 8.0 Hz, 2H), 7.37-7.26 (m, 6H), 4.14 (s, 2H), 
3.29 (s, 2H), 2.35 (s, 3H), 2.26-2.04 (m, 8H).  
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3β-(3′,4′-Dichlorophenyl)-3α−(4″-trifluoromethanephenyl)methoxy-8-methyl-8–azabicyclo 
[3.2.1]octane (60q). 
General procedure G. This compound was obtained as a light yellow oil (300 mg, 89% 
yield) and converted into an oxalate salt (General Procedure A) which was obtained as a white 
solid. 1H-NMR (free base, CDCl3): δ 7.60 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 2.4 Hz, 1H), 7.37 (q, J 
= 4.0 Hz, 3H), 7.25 (d, J = 8.8 Hz, 1H), 4.15 (s, 2H), 3.29 (s, 2H), 2.35 (s, 3H), 2.30-2.02 (m, 
8H). Anal. Calcd for C22H22Cl2F3NO•C2H2O4: C, 53.95; H, 4.53; N, 2.62. Found: C, 54.18; H, 
4.55; N, 2.60. 
 
 
General procedure H. β-elimination. 
 The tertiary alcohol (55a-e) was dissolved in CH2Cl2 (10 mL) and trifluoroacetic acid (1 
equiv.) was added to the solution. The reaction mixture was stirred at room temperature for 2 h. 
After the completion of the reaction, water was added to it. The aqueous layer was extracted with 
CH2Cl2 (3 × 30 mL). The combined organic fractions were dried (Na2SO4) and the solvent 
removed under reduced pressure to afford the product (66a-e). 
 
 
8–Ethoxycarbonyl-3-phenyl-8-azabicyclo[3.2.1]oct-2-ene (66a). 
General procedure H. This compound was obtained as a colorless oil (189 mg, 68% 
yield). 1H-NMR (CDCl3): δ 7.37-7.24 (m, 5H), 6.43 (s, 1H), 4.56 (s, 2H), 4.13 (q, J = 7.2 Hz, 
2H), 3.14 (s, 1H), 2.26-1.68 (m, 5H), 1.25 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ 154.5, 139.9, 
135.3, 128.5, 127.5, 124.9, 61.0, 53.3, 52.1, 36.34, 34.9, 30.2, 14.8. 
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8–Ethoxycarbonyl-3-(4′-chlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene (66b). 
General procedure H. This compound was obtained as a colorless oil (592 mg, 90% 
yield). 1H-NMR (CDCl3): δ 7.33-7.21 (m, 4H), 6.41 (s, 1H), 4.55 (s, 2H), 4.13 (q, J = 7.2 Hz, 
2H), 3.05 (s, 1H), 2.20-1.70 (m, 5H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3): δ 154.5, 138.3, 
133.3, 129.2, 128.6, 126.5, 126.3, 61.2, 53.3, 52.0, 36.4, 34.9, 29.8, 14.8. 
 
 
8–Ethoxycarbonyl-3-(4′-fluorophenyl)-8-azabicyclo[3.2.1]oct-2-ene (66c). 
General procedure H. This compound was obtained as a colorless oil (434 mg, 92.5% 
yield). 1H-NMR (CDCl3): δ 7.26-7.19 (m, 2H), 6.94-6.89 (m, 2H), 6.29 (s, 1H), 4.48 (s, 2H), 
4.07 (q, J = 7.2 Hz, 2H), 3.04 (s, 1H), 2.15-1.89 (m, 5H), 1.18 (t, J = 7.2 Hz, 3H). 13C-NMR 
(CDCl3): δ 163.5, 161.1, 154.4, 136.0, 128.4, 126.6, 115.3, 61.1, 53.3, 52.0, 36.5, 34.2, 29.4, 
14.7. 
 
 
8–Ethoxycarbonyl-3-(4′-trifluoromethanephenyl)-8-azabicyclo[3.2.1]oct-2-ene (66d). 
General procedure H. This compound was obtained as a colorless oil (230 mg, 92% 
yield). 1H-NMR (CDCl3): δ 7.56 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 6.51 (s, 1H), 4.57 
(s, 2H), 4.14 (q, J = 7.2 Hz, 2H), 3.14 (s, 1H), 2.25-1.70 (m, 5H), 1.24 (t, J = 7.2 Hz, 3H). 13C-
NMR (CDCl3): δ 154.6, 143.5, 130.8, 130.4, 129.4, 125.5, 125.3, 123.0, 61.3, 53.4, 52.1, 35.9, 
34.3, 29.5, 14.9. 
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8–Ethoxycarbonyl-3-(3′, 4′-dichlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene (66e). 
General procedure H. This compound was obtained as a colorless oil (415 mg, 90% 
yield). 1H-NMR (CDCl3): δ 7.40-7.34 (m, 2H), 7.17 (d, J = 8.4 Hz, 1H), 6.43 (s, 1H), 4.55 (s, 
2H), 4.11 (q, J = 6.8 Hz, 2H), 3.06 (s, 1H), 2.06-1.93 (m, 5H), 1.24 (t, J = 7.2 Hz, 3H). 13C-NMR 
(CDCl3): δ 154.5, 140.0, 132.6, 131.3, 130.3, 127.0, 124.3, 61.2, 53.3, 52.0, 35.8, 34.8, 29.5, 
14.8. 
 
 
3-Phenyl-2-nortropene (65a). 
General procedure F. This compound was obtained as colorless oil (38 mg, 29% yield) 
and converted into an oxalate salt (General Procedure A) which was obtained as a white solid. 
1H-NMR (free base, CDCl3): δ 7.37-7.20 (m, 5H), 6.44 (d, J = 5.6 Hz, 1H), 3.82 (dt, JA = 5.6 Hz, 
JAB = 24.4 Hz, 2H), 2.85 (dd, JA = 4.0 Hz, JAB = 16.8 Hz, 1H), 2.26-1.61 (m, 5H). 
 
 
3-(4′-Chlorophenyl)-2-nortropene (65b). 
General procedure F. This compound was obtained as colorless oil (399 mg, 92% yield) 
and converted into an oxalate salt (General Procedure A) which was obtained as a white solid. 
1H-NMR (free base, CDCl3): δ 7.28-7.18 (m, 4H), 6.42 (d, J = 3.6 Hz, 1H), 3.81 (dt, JA = 5.6 Hz, 
JAB = 22.8 Hz, 2H), 2.80 (dd, JA = 4.4 Hz, JAB = 16.8 Hz, 1H), 2.27-1.18 (m, 5H). 
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3-(4′-Fluorophenyl)-2-nortropene (65c). 
General procedure F. This compound was obtained as colorless oil (160 mg, 60% yield) 
and converted into an oxalate salt (General Procedure A) which was obtained as a white solid. 
1H-NMR (free base, CDCl3): δ 7.32-7.28 (m, 2H), 7.00-76.83 (m, 2H), 6.36 (d, J = 5.6 Hz, 1H), 
4.06 (t, J = 4.4 Hz, 1H), 3.93 (t, J = 4.8 Hz, 1H), 2.80 (d, J = 4.4 Hz, 1H), 2.21-1.16 (m, 5H). 
 
 
3-(4′-trifluoromethanephenyl)-2-nortropene (65d). 
General procedure F. This compound was obtained as colorless oil (150 mg, 88% yield) 
and converted into an oxalate salt (General Procedure A) which was obtained as a white solid. 
1H-NMR (free base, CDCl3): δ 7.55 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 6.53 (d, J = 5.6 
Hz, 1H), 3.88 (t, J = 6.0 Hz, 1H), 3.83 (t, J = 5.6 Hz, 1H), 2.89 (dd, JA = 4.0 Hz, JAB = 16.8 Hz, 
1H), 2.25-1.64 (m, 5H). 
 
 
3-(3′, 4′-dichlorophenyl)-2-nortropene (65e). 
General procedure F. This compound was obtained as colorless oil (277 mg, 95% yield) 
and converted into an oxalate salt (General Procedure A) which was obtained as a white solid. 
1H-NMR (free base, CDCl3): δ 7.40-7.33 (m, 2H), 7.17 (d, J = 8.4 Hz, 1H), 6.46 (d, J = 5.6 Hz, 
1H), 3.86 (t, J = 5.2 Hz, 1H), 3.81 (t, J = 5.6 Hz, 1H), 2.82 (dd, JA = 4.4 Hz, JAB = 17.2 Hz, 1H), 
2.17-1.86 (m, 5H). 
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3β-(4′-Chlorophenyl)-3α-diphenylmethoxytropane (67a). 
 Tertiary alcohol 41b was heated to 185oC and chlorodiphenylmethane (0.84 mL, 
2.4 equiv.) was added dropwise to the flask over 5 minutes. Evolution of HCl gas over 30 
minutes resulted in a bronze oil which solidified to a glass upon cooling. The solid was dissolved 
in chloroform and purification was done by column chromatography (CHCl3/CH3OH/NH4OH, 
97:2.5:0.5) to yield 67a in 35% yield as a yellow oil. It was converted into an oxalate salt 
(General Procedure A). 1H-NMR (free base, CDCl3): δ 7.20-6.97 (m, 14H), 4.99 (s, 1H), 3.32 (s, 
2H), 2.52-2.49 (m, 4H), 2.38 (s, 3H), 2.09-1.88 (m, 4H). 13C-NMR (free base, CDCl3): δ 144.3, 
143.0, 133.1, 128.2, 128.1, 127.7, 126.9, 126.6, 78.7, 76.9, 60.7, 40.4, 39.6, 25.1. 
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APPENDIX 
 
 
1.  Crystal data and structure refinement for 55a. 
   
Table 1.1   
Identification code               mlt42m 
Empirical formula                C16H21NO3 
Formula weight                    275.34 
Temperature                         150(2) K 
Wavelength                          0.71073 Å 
Crystal system, space group       Monoclinic, P21/n  
Unit cell dimensions              a = 7.0649(5) Å                    α = 90 deg.  
                                               b = 16.7415(13) Å                β = 98.951(2) deg.  
                                               c = 11.8086(9) Å                  γ = 90 deg.  
Volume                                1379.68(18) Å3  
Z, Calculated density          4,  1.326 Mg/m3  
Absorption coefficient            0.091 mm-1  
F(000)                              592  
Crystal size                       0.60 x 0.40 x 0.10 mm  
Theta range for data collection   2.13 to 30.60 deg.  
Limiting indices                  -10 ≤ h ≤ 10, -23 ≤ k ≤ 23, -16 ≤ l ≤ 16  
Reflections collected / unique    22821 / 4208 [R(int) = 0.0253]  
Completeness to theta = 30.60     99.4 %  
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Absorption correction             Empirical  
Max. and min. transmission        1.000000 and 0.951697  
   
Refinement method                 Full-matrix least-squares on F2  
Data / restraints / parameters    4208 / 0 / 265  
Goodness-of-fit on F2             1.027  
Final R indices [I>2sigma(I)]     R1 = 0.0335, wR2 = 0.0877  
R indices (all data)              R1 = 0.0416, wR2 = 0.0934  
Largest diff. peak and hole       0.373 and -0.217 e.A^-3 
 
Table 1.2.  Atomic coordinates ( x104) and equivalent isotropic displacement parameters (Å2 x 
103) for MLT42M. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          C(1)        -1225(1)        880(1)       5004(1)       16(1)  
          C(2)          613(1)       1381(1)       5254(1)       16(1)  
          C(3)          371(1)       2163(1)       5908(1)       15(1)  
          C(4)        -1603(1)       2548(1)       5491(1)       16(1)  
          C(5)        -3238(1)       1943(1)       5246(1)       16(1)  
          C(6)        -3442(1)       1366(1)       6240(1)       20(1)  
          C(7)        -2095(1)        657(1)       6082(1)       21(1)  
          N(8)        -2721(1)       1391(1)       4372(1)       16(1)  
          C(9)        -4020(1)       1153(1)       3475(1)       15(1)  
          O(10)       -5456(1)       1532(1)       3079(1)       20(1)  
          O(11)       -3511(1)        458(1)       3029(1)       19(1)  
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          C(12)       -4592(2)        235(1)       1931(1)       23(1)  
          C(13)       -3535(2)       -449(1)       1490(1)       27(1)  
          O(14)         483(1)       1943(1)       7089(1)       18(1)  
          C(15)        1976(1)       2754(1)       5767(1)       15(1)  
          C(16)        2114(1)       3094(1)       4700(1)       19(1)  
          C(17)        3517(1)       3660(1)       4585(1)       23(1)  
          C(18)        4808(1)       3896(1)       5534(1)       23(1)  
          C(19)        4722(1)       3550(1)       6591(1)       22(1)  
          C(20)        3327(1)       2979(1)       6705(1)       18(1)  
         ________________________________________________________________  
  
  
           Table 1.3.  Bond lengths [Å] and angles [deg] for MLT42M.  
           _____________________________________________________________  
   
            C(1)-N(8)                     1.4695(10)  
            C(1)-C(2)                     1.5346(12)  
            C(1)-C(7)                     1.5429(13)  
            C(2)-C(3)                     1.5440(12)  
            C(3)-O(14)                    1.4331(10)  
            C(3)-C(15)                    1.5328(12)  
            C(3)-C(4)                     1.5457(11)  
            C(4)-C(5)                     1.5293(12)  
            C(5)-N(8)                     1.4723(11)  
            C(5)-C(6)                     1.5441(12)  
            C(6)-C(7)                     1.5513(13)  
            N(8)-C(9)                     1.3497(10)  
            C(9)-O(10)                    1.2257(10)  
            C(9)-O(11)                    1.3486(10)  
            O(11)-C(12)                   1.4473(10)  
            C(12)-C(13)                   1.5031(14)  
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            C(15)-C(20)                   1.3972(12)  
            C(15)-C(16)                   1.3991(12)  
            C(16)-C(17)                   1.3926(13)  
            C(17)-C(18)                   1.3884(14)  
            C(18)-C(19)                   1.3859(14)  
            C(19)-C(20)                   1.3934(13)  
   
            N(8)-C(1)-C(2)              107.47(7)  
            N(8)-C(1)-C(7)              102.28(7)  
            C(2)-C(1)-C(7)              114.08(7)  
            C(1)-C(2)-C(3)              113.76(7)  
            O(14)-C(3)-C(15)            110.03(7)  
            O(14)-C(3)-C(2)             105.94(7)  
            C(15)-C(3)-C(2)             110.60(7)  
            O(14)-C(3)-C(4)             109.13(7)  
            C(15)-C(3)-C(4)             110.04(7)  
            C(2)-C(3)-C(4)              111.01(7)  
            C(5)-C(4)-C(3)              113.73(7)  
            N(8)-C(5)-C(4)              106.57(7)  
            N(8)-C(5)-C(6)              101.73(7)  
            C(4)-C(5)-C(6)              115.27(7)  
            C(5)-C(6)-C(7)              104.80(7)  
            C(1)-C(7)-C(6)              104.13(7)  
            C(9)-N(8)-C(1)              125.05(7)  
            C(9)-N(8)-C(5)              121.51(7)  
            C(1)-N(8)-C(5)              104.28(6)  
            O(10)-C(9)-O(11)            123.54(8)  
            O(10)-C(9)-N(8)             124.61(8)  
            O(11)-C(9)-N(8)             111.80(7)  
            C(9)-O(11)-C(12)            115.91(7)  
            O(11)-C(12)-C(13)           106.61(8)  
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            C(20)-C(15)-C(16)           117.98(8)  
            C(20)-C(15)-C(3)            120.89(8)  
            C(16)-C(15)-C(3)            121.12(7)  
            C(17)-C(16)-C(15)           120.98(8)  
            C(18)-C(17)-C(16)           120.24(9)  
            C(19)-C(18)-C(17)           119.46(9)  
            C(18)-C(19)-C(20)           120.31(9)  
            C(19)-C(20)-C(15)           120.98(8)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
             
   
    Table 1.4.  Anisotropic displacement parameters (Å2 x103) for MLT42M.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    C(1)     17(1)      14(1)      17(1)      -1(1)      -2(1)       4(1)  
    C(2)     15(1)      16(1)      17(1)      -2(1)       0(1)       4(1)  
    C(3)     15(1)      15(1)      13(1)       0(1)       0(1)       2(1)  
    C(4)     15(1)      14(1)      17(1)      -2(1)       1(1)       3(1)  
    C(5)     14(1)      16(1)      16(1)      -2(1)       1(1)       3(1)  
    C(6)     19(1)      23(1)      19(1)       2(1)       4(1)       0(1)  
    C(7)     22(1)      18(1)      21(1)       4(1)       0(1)       0(1)  
    N(8)     16(1)      15(1)      16(1)      -2(1)      -2(1)       4(1)  
    C(9)     16(1)      15(1)      14(1)       2(1)       1(1)      -1(1)  
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    O(10)    18(1)      22(1)      19(1)       2(1)      -2(1)       2(1)  
    O(11)    23(1)      17(1)      16(1)      -3(1)      -3(1)       1(1)  
    C(12)    27(1)      22(1)      16(1)      -3(1)      -5(1)      -2(1)  
    C(13)    35(1)      24(1)      22(1)      -7(1)       2(1)      -3(1)  
    O(14)    22(1)      19(1)      13(1)       0(1)       1(1)       1(1)  
    C(15)    14(1)      15(1)      17(1)      -1(1)       2(1)       3(1)  
    C(16)    18(1)      21(1)      18(1)       1(1)       1(1)       2(1)  
    C(17)    22(1)      22(1)      25(1)       5(1)       5(1)       2(1)  
    C(18)    18(1)      19(1)      32(1)      -1(1)       6(1)      -1(1)  
    C(19)    16(1)      24(1)      24(1)      -6(1)       2(1)      -1(1)  
    C(20)    16(1)      21(1)      17(1)      -3(1)       2(1)       2(1)  
    _______________________________________________________________________  
  
         Table 1.5.  Hydrogen coordinates ( x104) and isotropic  
         displacement parameters (Å2 x103) for MLT42M.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1)        -1009(17)       429(7)       4527(10)      18(3)  
          H(2A)        1038(18)      1511(7)       4510(11)      19(3)  
          H(2B)        1647(18)      1070(8)       5710(11)      21(3)  
          H(4A)       -1578(17)      2850(7)       4766(11)      20(3)  
          H(4B)       -1873(18)      2927(7)       6079(11)      21(3)  
          H(5)        -4409(17)      2219(7)       4947(10)      19(3)  
          H(6A)       -3104(19)      1625(8)       7008(11)      25(3)  
          H(6B)       -4810(20)      1189(8)       6164(12)      27(3)  
          H(7A)       -1107(19)       569(8)       6768(11)      26(3)  
          H(7B)       -2847(19)       164(8)       5930(11)      27(3)  
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          H(12A)      -5890(20)        78(8)       2045(12)      30(3)  
          H(12B)      -4690(20)       694(9)       1422(12)      32(3)  
          H(13A)      -3430(20)      -916(10)      2014(14)      41(4)  
          H(13B)      -4180(20)      -616(9)        751(13)      37(4)  
          H(12C)      -2200(20)      -284(9)       1386(14)      43(4)  
          H(14)         160(20)      2348(10)      7447(13)      38(4)  
          H(16)        1203(19)      2923(8)       4020(11)      26(3)  
          H(17)        3610(20)      3893(8)       3821(12)      32(3)  
          H(18)        5790(20)      4291(9)       5436(12)      34(4)  
          H(19)        5637(19)      3689(8)       7255(12)      27(3)  
          H(20)        3246(17)      2741(7)       7439(11)      21(3)  
         ________________________________________________________________  
  
         Table 1.6.  Torsion angles [deg] for MLT42M.  
         ________________________________________________________________  
   
          N(8)-C(1)-C(2)-C(3)                                  56.05(9)  
          C(7)-C(1)-C(2)-C(3)                                 -56.58(9)  
          C(1)-C(2)-C(3)-O(14)                                 80.36(8)  
          C(1)-C(2)-C(3)-C(15)                               -160.44(7)  
          C(1)-C(2)-C(3)-C(4)                                 -37.99(9)  
          O(14)-C(3)-C(4)-C(5)                                -77.14(8)  
          C(15)-C(3)-C(4)-C(5)                                162.03(7)  
          C(2)-C(3)-C(4)-C(5)                                  39.26(9)  
          C(3)-C(4)-C(5)-N(8)                                 -58.16(9)  
          C(3)-C(4)-C(5)-C(6)                                  53.87(9)  
          N(8)-C(5)-C(6)-C(7)                                  27.37(8)  
          C(4)-C(5)-C(6)-C(7)                                 -87.48(9)  
          N(8)-C(1)-C(7)-C(6)                                 -27.27(8)  
          C(2)-C(1)-C(7)-C(6)                                  88.43(8)  
          C(5)-C(6)-C(7)-C(1)                                  -0.13(9)  
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          C(2)-C(1)-N(8)-C(9)                                 139.22(8)  
          C(7)-C(1)-N(8)-C(9)                                -100.37(9)  
          C(2)-C(1)-N(8)-C(5)                                 -73.93(8)  
          C(7)-C(1)-N(8)-C(5)                                  46.48(8)  
          C(4)-C(5)-N(8)-C(9)                                -136.87(8)  
          C(6)-C(5)-N(8)-C(9)                                 102.02(9)  
          C(4)-C(5)-N(8)-C(1)                                  74.80(8)  
          C(6)-C(5)-N(8)-C(1)                                 -46.31(8)  
          C(1)-N(8)-C(9)-O(10)                                166.71(8)  
          C(5)-N(8)-C(9)-O(10)                                 25.15(13)  
          C(1)-N(8)-C(9)-O(11)                                -15.86(12)  
          C(5)-N(8)-C(9)-O(11)                               -157.42(7)  
          O(10)-C(9)-O(11)-C(12)                                9.53(12)  
          N(8)-C(9)-O(11)-C(12)                              -167.93(8)  
          C(9)-O(11)-C(12)-C(13)                              168.36(8)  
          O(14)-C(3)-C(15)-C(20)                                2.42(11)  
          C(2)-C(3)-C(15)-C(20)                              -114.28(8)  
          C(4)-C(3)-C(15)-C(20)                               122.71(8)  
          O(14)-C(3)-C(15)-C(16)                             -176.51(7)  
          C(2)-C(3)-C(15)-C(16)                                66.79(10)  
          C(4)-C(3)-C(15)-C(16)                               -56.22(10)  
          C(20)-C(15)-C(16)-C(17)                              -2.12(13)  
          C(3)-C(15)-C(16)-C(17)                              176.85(8)  
          C(15)-C(16)-C(17)-C(18)                               0.01(14)  
          C(16)-C(17)-C(18)-C(19)                               1.71(14)  
          C(17)-C(18)-C(19)-C(20)                              -1.27(14)  
          C(18)-C(19)-C(20)-C(15)                              -0.89(14)  
          C(16)-C(15)-C(20)-C(19)                               2.56(13)  
          C(3)-C(15)-C(20)-C(19)                             -176.41(8)  
         ________________________________________________________________  
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         Symmetry transformations used to generate equivalent atoms:  
           
  
  
 Table 1.7.  Hydrogen bonds for MLT42M [Å and deg.].  
 ____________________________________________________________________________  
   
 D-H...A                      d(D-H)      d(H...A)    d(D...A)    <(DHA)  
   
 O(14)-H(14)...O(10)#1        0.849(16)   2.089(17)   2.9272(10)  169.1(15)  
 ____________________________________________________________________________  
   
 Symmetry transformations used to generate equivalent atoms:  
 #1 x+1/2,-y+1/2,z+1/2      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 125
2.  Crystal data and structure refinement for 60a. 
   
      Table 2.1 
 
      Identification code               mlt45  
   
      Empirical formula                 C21H26NO+ . C2O4H-  
   
      Formula weight                    397.46  
   
      Temperature                       295(2) K  
   
      Wavelength                        0.71073 Å  
   
      Crystal system, space group       Monoclinic,  P21/c  
   
      Unit cell dimensions              a = 13.742(2) Å   α = 90 deg.  
                                        b = 11.131(2) Å   β = 113.726(3) deg.  
                                        c = 14.837(2) Å   γ = 90 deg.  
   
      Volume                            2077.6(5) Å3  
   
      Z, Calculated density             4,  1.271 Mg/m3  
   
      Absorption coefficient            0.089 mm-1  
   
      F(000)                            848  
   
      Crystal size                      0.50 x 0.40 x 0.20 mm  
   
      Theta range for data collection   2.37 to 22.49 deg.  
   
      Limiting indices                  -14 ≤ h ≤ 14, -11 ≤ k ≤ 11, -15 ≤ l ≤ 15  
   
      Reflections collected / unique    17041 / 2695 [R(int) = 0.0236]  
   
      Completeness to theta = 22.49     99.9 %  
   
      Absorption correction             Empirical  
   
      Max. and min. transmission        0.952135 and 0.840080  
   
      Refinement method                 Full-matrix least-squares on F2  
   
      Data / restraints / parameters    2695 / 489 / 393  
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      Goodness-of-fit on F2             1.071  
   
      Final R indices [I>2σ(I)]         R1 = 0.0302, wR2 = 0.0797  
   
      R indices (all data)              R1 = 0.0348, wR2 = 0.0825  
   
      Extinction coefficient            0.0178(13)  
   
      Largest diff. peak and hole       0.171 and -0.123 e.Å-3  
 
 
  
         Table 2.2.  Atomic coordinates ( x104) and equivalent isotropic  
         displacement parameters (Å2 x103) for Mlt45.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          C(1)         8499(1)       2279(1)       1623(1)       42(1)  
          C(2)         7975(1)       3313(1)       1936(1)       42(1)  
          C(3)         7049(1)       2932(1)       2211(1)       39(1)  
          C(4)         7326(1)       1741(1)       2789(1)       40(1)  
          C(5)         7904(1)        823(1)       2413(1)       43(1)  
          C(6)         7351(1)        528(2)       1315(1)       50(1)  
          C(7)         7753(1)       1483(2)        796(1)       50(1)  
          N(8)         8923(1)       1411(1)       2477(1)       41(1)  
          C(9)         9719(1)        535(2)       2413(1)       56(1)  
          C(10)        6761(1)       3883(1)       2816(1)       44(1)  
          C(11)        7356(2)       4895(2)       3215(1)       58(1)  
          C(12)        7017(2)       5733(2)       3721(2)       75(1)  
          C(13)        6090(2)       5576(2)       3835(2)       75(1)  
          C(14)        5499(2)       4563(2)       3460(2)       74(1)  
          C(15)        5831(2)       3719(2)       2958(1)       62(1)  
          O(16)        6100(1)       2661(1)       1341(1)       42(1)  
          C(17)        5685(1)       3644(2)        666(1)       53(1)  
          C(18)        4540(5)       3512(16)       163(7)       50(1)  
          C(18B)       4510(7)       3400(20)       -35(10)      48(2)  
          C(19)        3898(4)       3930(5)        616(4)       64(1)  
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          C(19B)       3646(5)       3603(8)        201(6)       66(2)  
          C(20)        2808(3)       3814(5)        146(4)       86(2)  
          C(20B)       2611(6)       3357(13)      -445(8)       85(2)  
          C(21)        2352(4)       3287(9)       -777(5)       88(2)  
          C(21B)       2450(5)       2854(8)      -1339(7)       91(2)  
          C(22)        2974(4)       2904(6)      -1243(5)       85(2)  
          C(22B)       3291(6)       2629(7)      -1601(6)       89(2)  
          C(23)        4069(4)       3025(8)       -764(5)       63(1)  
          C(23B)       4315(6)       2910(13)      -949(7)       65(2)  
          C(24)       10126(1)       3122(1)       4821(1)       36(1)  
          C(25)       10280(1)       1864(1)       5294(1)       38(1)  
          O(26)       10153(1)       3988(1)       5389(1)       52(1)  
          O(27)        9992(1)       3208(1)       3954(1)       53(1)  
          O(28)        9857(1)       1031(1)       4662(1)       59(1)  
          O(29)       10764(1)       1733(1)       6168(1)       67(1)  
         ________________________________________________________________  
   
 
 
           Table 2.3.  Bond lengths [Å] and angles [deg] for Mlt45.  
           _____________________________________________________________  
   
            C(1)-N(8)                     1.5116(18)  
            C(1)-C(2)                     1.526(2)  
            C(1)-C(7)                     1.527(2)  
            C(2)-C(3)                     1.544(2)  
            C(3)-O(16)                    1.4507(16)  
            C(3)-C(10)                    1.538(2)  
            C(3)-C(4)                     1.5411(19)  
            C(4)-C(5)                     1.529(2)  
            C(5)-N(8)                     1.5134(19)  
            C(5)-C(6)                     1.531(2)  
            C(6)-C(7)                     1.540(2)  
            N(8)-C(9)                     1.4973(18)  
            C(10)-C(11)                   1.378(2)  
            C(10)-C(15)                   1.388(2)  
            C(11)-C(12)                   1.389(2)  
            C(12)-C(13)                   1.361(3)  
            C(13)-C(14)                   1.370(3)  
            C(14)-C(15)                   1.385(3)  
            O(16)-C(17)                   1.4369(17)  
            C(17)-C(18)                   1.453(6)  
            C(17)-C(18B)                  1.553(9)  
            C(18)-C(23)                   1.374(5)  
            C(18)-C(19)                   1.387(5)  
            C(18B)-C(23B)                 1.384(6)  
 128
            C(18B)-C(19B)                 1.386(6)  
            C(19)-C(20)                   1.381(5)  
            C(19B)-C(20B)                 1.385(6)  
            C(20)-C(21)                   1.386(5)  
            C(20B)-C(21B)                 1.374(6)  
            C(21)-C(22)                   1.365(5)  
            C(21B)-C(22B)                 1.382(6)  
            C(22)-C(23)                   1.389(5)  
            C(22B)-C(23B)                 1.385(6)  
            C(24)-O(27)                   1.2266(16)  
            C(24)-O(26)                   1.2713(16)  
            C(24)-C(25)                   1.5422(19)  
            C(25)-O(29)                   1.2054(16)  
            C(25)-O(28)                   1.2796(16)  
   
            N(8)-C(1)-C(2)              107.26(11)  
            N(8)-C(1)-C(7)              102.17(12)  
            C(2)-C(1)-C(7)              115.81(13)  
            C(1)-C(2)-C(3)              114.44(12)  
            O(16)-C(3)-C(10)            108.20(11)  
            O(16)-C(3)-C(4)             104.37(11)  
            C(10)-C(3)-C(4)             109.38(11)  
            O(16)-C(3)-C(2)             111.28(11)  
            C(10)-C(3)-C(2)             113.45(11)  
            C(4)-C(3)-C(2)              109.75(11)  
            C(5)-C(4)-C(3)              114.87(11)  
            N(8)-C(5)-C(4)              106.95(11)  
            N(8)-C(5)-C(6)              102.11(12)  
            C(4)-C(5)-C(6)              115.04(13)  
            C(5)-C(6)-C(7)              105.06(12)  
            C(1)-C(7)-C(6)              104.98(12)  
            C(9)-N(8)-C(1)              114.04(11)  
            C(9)-N(8)-C(5)              113.37(12)  
            C(1)-N(8)-C(5)              100.91(11)  
            C(11)-C(10)-C(15)           117.66(15)  
            C(11)-C(10)-C(3)            124.50(14)  
            C(15)-C(10)-C(3)            117.83(14)  
            C(10)-C(11)-C(12)           120.75(19)  
            C(13)-C(12)-C(11)           121.0(2)  
            C(12)-C(13)-C(14)           119.13(18)  
            C(13)-C(14)-C(15)           120.4(2)  
            C(14)-C(15)-C(10)           121.05(19)  
            C(17)-O(16)-C(3)            115.10(11)  
            O(16)-C(17)-C(18)           108.9(8)  
            O(16)-C(17)-C(18B)          110.3(10)  
            C(18)-C(17)-C(18B)           11.1(5)  
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            C(23)-C(18)-C(19)           118.8(5)  
            C(23)-C(18)-C(17)           122.0(5)  
            C(19)-C(18)-C(17)           119.1(5)  
            C(23B)-C(18B)-C(19B)        117.7(7)  
            C(23B)-C(18B)-C(17)         117.7(6)  
            C(19B)-C(18B)-C(17)         124.6(6)  
            C(20)-C(19)-C(18)           119.8(5)  
            C(20B)-C(19B)-C(18B)        122.6(7)  
            C(19)-C(20)-C(21)           120.4(5)  
            C(21B)-C(20B)-C(19B)        118.0(7)  
            C(22)-C(21)-C(20)           120.4(5)  
            C(20B)-C(21B)-C(22B)        121.2(7)  
            C(21)-C(22)-C(23)           118.8(5)  
            C(21B)-C(22B)-C(23B)        119.5(6)  
            C(18)-C(23)-C(22)           121.8(5)  
            C(18B)-C(23B)-C(22B)        121.0(7)  
            O(27)-C(24)-O(26)           126.02(12)  
            O(27)-C(24)-C(25)           118.86(11)  
            O(26)-C(24)-C(25)           115.12(11)  
            O(29)-C(25)-O(28)           126.25(13)  
            O(29)-C(25)-C(24)           121.03(12)  
            O(28)-C(25)-C(24)           112.72(11)  
           _____________________________________________________________  
   
 
             
    Table 2.4.  Anisotropic displacement parameters (Å2 x103) for Mlt45.  
    The anisotropic displacement factor exponent takes the form:  
    -2π2[h2a*2U11 + ... + 2hka*b*U12]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    C(1)     45(1)      43(1)      46(1)       0(1)      25(1)      -4(1)  
    C(2)     45(1)      34(1)      50(1)       2(1)      21(1)      -5(1)  
    C(3)     42(1)      32(1)      43(1)       1(1)      18(1)      -1(1)  
    C(4)     45(1)      36(1)      45(1)       5(1)      23(1)       2(1)  
    C(5)     51(1)      32(1)      49(1)       4(1)      24(1)       1(1)  
    C(6)     57(1)      39(1)      55(1)      -8(1)      23(1)      -6(1)  
    C(7)     57(1)      54(1)      44(1)      -6(1)      24(1)      -2(1)  
    N(8)     45(1)      39(1)      41(1)      -6(1)      19(1)       3(1)  
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    C(9)     57(1)      55(1)      60(1)      -8(1)      29(1)      13(1)  
    C(10)    52(1)      36(1)      47(1)       5(1)      22(1)       9(1)  
    C(11)    65(1)      43(1)      65(1)      -8(1)      25(1)       2(1)  
    C(12)    93(1)      52(1)      79(1)     -18(1)      34(1)       8(1)  
    C(13)   101(2)      58(1)      71(1)      -4(1)      41(1)      30(1)  
    C(14)    81(1)      73(1)      86(1)      -2(1)      52(1)      18(1)  
    C(15)    68(1)      55(1)      76(1)      -5(1)      42(1)       4(1)  
    O(16)    45(1)      31(1)      48(1)       8(1)      17(1)       0(1)  
    C(17)    55(1)      42(1)      57(1)      16(1)      19(1)      -1(1)  
    C(18)    53(2)      38(4)      56(3)      21(3)      18(2)       5(2)  
    C(18B)   49(3)      38(4)      58(4)      18(4)      21(3)       5(3)  
    C(19)    55(2)      67(3)      69(3)      23(2)      24(2)       9(2)  
    C(19B)   58(3)      66(4)      81(4)      21(3)      35(3)       7(3)  
    C(20)    56(2)     101(3)     100(3)      48(3)      32(2)      14(2)  
    C(20B)   51(3)      87(5)     108(6)      37(5)      24(4)       3(4)  
    C(21)    49(3)      91(4)      99(4)      51(4)       5(2)      -7(3)  
    C(21B)   67(4)      63(4)     110(5)      30(3)       2(4)       7(4)  
    C(22)    67(3)      71(3)      91(3)      28(2)       6(3)     -12(3)  
    C(22B)   96(4)      62(3)      80(4)       7(3)       5(3)       6(3)  
    C(23)    61(2)      50(3)      70(3)      15(2)      18(2)      -1(2)  
    C(23B)   69(4)      54(3)      64(4)       9(3)      18(3)      13(4)  
    C(24)    43(1)      26(1)      39(1)      -3(1)      17(1)      -2(1)  
    C(25)    46(1)      28(1)      42(1)       0(1)      21(1)       2(1)  
    O(26)    86(1)      25(1)      51(1)      -5(1)      34(1)       0(1)  
    O(27)    85(1)      33(1)      42(1)       0(1)      27(1)      -1(1)  
    O(28)    86(1)      23(1)      53(1)      -1(1)      14(1)      -4(1)  
    O(29)   106(1)      40(1)      44(1)       4(1)      17(1)       2(1)  
    _______________________________________________________________________  
   
  
        Table 2.5.  Hydrogen coordinates ( x104) and isotropic  
         displacement parameters (Å2 x103) for Mlt45.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1)         9101(12)      2575(13)      1508(10)      44(4)  
          H(2A)        8524(12)      3678(13)      2500(11)      44(4)  
          H(2B)        7717(11)      3919(14)      1403(11)      45(4)  
          H(4A)        7780(11)      1925(13)      3487(11)      47(4)  
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          H(4B)        6672(12)      1397(12)      2770(10)      40(4)  
          H(5)         8110(11)       120(14)      2844(10)      47(4)  
          H(6A)        7567(12)      -293(16)      1186(11)      57(4)  
          H(6B)        6544(13)       575(14)      1093(11)      52(4)  
          H(7A)        8130(12)      1114(14)       446(12)      56(4)  
          H(7B)        7185(13)      1938(14)       335(12)      54(4)  
          H(8)         9264(12)      1806(15)      3068(12)      56(5)  
          H(9A)        9386            30          1847          83  
          H(9B)        9986            48          2996          83  
          H(9C)       10297           965          2355          83  
          H(11)        8036(15)      5039(17)      3152(12)      77(6)  
          H(12)        7444(18)      6450(20)      3971(16)     106(8)  
          H(13)        5834(17)      6150(20)      4163(15)      94(6)  
          H(14)        4870(16)      4417(18)      3543(14)      86(6)  
          H(15)        5382(14)      3027(18)      2651(13)      75(6)  
          H(17A)       5825(13)      4403(18)      1030(13)      69(5)  
          H(17B)       6061(13)      3670(15)       206(13)      65(5)  
          H(19)        4200          4287          1234          77  
          H(19B)       3765          3918           817          79  
          H(20)        2377          4091           450         103  
          H(20B)       2042          3527          -277         102  
          H(21)        1618          3193         -1081         105  
          H(21B)       1764          2662         -1777         109  
          H(22)        2669          2569         -1869         102  
          H(22B)       3170          2290         -2210         107  
          H(23)        4496          2769         -1080          76  
          H(23B)       4880          2767         -1129          78  
          H(26)       10000          5000          5000         130(11)  
          H(28)       10000             0          5000         112(10)  
         ________________________________________________________________  
   
 
         Table 2.6.  Torsion angles [deg] for Mlt45.  
         ________________________________________________________________  
   
          N(8)-C(1)-C(2)-C(3)                                 -59.60(16)  
          C(7)-C(1)-C(2)-C(3)                                  53.70(18)  
          C(1)-C(2)-C(3)-O(16)                                -75.50(15)  
          C(1)-C(2)-C(3)-C(10)                                162.19(12)  
          C(1)-C(2)-C(3)-C(4)                                  39.51(17)  
          O(16)-C(3)-C(4)-C(5)                                 79.85(15)  
          C(10)-C(3)-C(4)-C(5)                               -164.56(12)  
          C(2)-C(3)-C(4)-C(5)                                 -39.49(17)  
          C(3)-C(4)-C(5)-N(8)                                  59.21(16)  
          C(3)-C(4)-C(5)-C(6)                                 -53.39(18)  
          N(8)-C(5)-C(6)-C(7)                                 -28.43(15)  
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          C(4)-C(5)-C(6)-C(7)                                  87.00(16)  
          N(8)-C(1)-C(7)-C(6)                                  29.62(15)  
          C(2)-C(1)-C(7)-C(6)                                 -86.58(16)  
          C(5)-C(6)-C(7)-C(1)                                  -0.70(17)  
          C(2)-C(1)-N(8)-C(9)                                -163.54(12)  
          C(7)-C(1)-N(8)-C(9)                                  74.22(15)  
          C(2)-C(1)-N(8)-C(5)                                  74.57(13)  
          C(7)-C(1)-N(8)-C(5)                                 -47.67(13)  
          C(4)-C(5)-N(8)-C(9)                                 163.58(12)  
          C(6)-C(5)-N(8)-C(9)                                 -75.23(15)  
          C(4)-C(5)-N(8)-C(1)                                 -74.06(13)  
          C(6)-C(5)-N(8)-C(1)                                  47.12(13)  
          O(16)-C(3)-C(10)-C(11)                             -133.73(14)  
          C(4)-C(3)-C(10)-C(11)                               113.15(16)  
          C(2)-C(3)-C(10)-C(11)                                -9.7(2)  
          O(16)-C(3)-C(10)-C(15)                               45.34(17)  
          C(4)-C(3)-C(10)-C(15)                               -67.78(17)  
          C(2)-C(3)-C(10)-C(15)                               169.34(14)  
          C(15)-C(10)-C(11)-C(12)                              -1.5(2)  
          C(3)-C(10)-C(11)-C(12)                              177.53(16)  
          C(10)-C(11)-C(12)-C(13)                               0.0(3)  
          C(11)-C(12)-C(13)-C(14)                               1.4(3)  
          C(12)-C(13)-C(14)-C(15)                              -1.1(3)  
          C(13)-C(14)-C(15)-C(10)                              -0.5(3)  
          C(11)-C(10)-C(15)-C(14)                               1.8(3)  
          C(3)-C(10)-C(15)-C(14)                             -177.33(16)  
          C(10)-C(3)-O(16)-C(17)                               64.31(14)  
          C(4)-C(3)-O(16)-C(17)                              -179.27(12)  
          C(2)-C(3)-O(16)-C(17)                               -60.97(15)  
          C(3)-O(16)-C(17)-C(18)                             -149.9(3)  
          C(3)-O(16)-C(17)-C(18B)                            -161.6(4)  
          O(16)-C(17)-C(18)-C(23)                             -98.6(14)  
          C(18B)-C(17)-C(18)-C(23)                              0(8)  
          O(16)-C(17)-C(18)-C(19)                              83.8(13)  
          C(18B)-C(17)-C(18)-C(19)                           -177(10)  
          O(16)-C(17)-C(18B)-C(23B)                           -96.1(18)  
          C(18)-C(17)-C(18B)-C(23B)                           179(11)  
          O(16)-C(17)-C(18B)-C(19B)                            82(2)  
          C(18)-C(17)-C(18B)-C(19B)                            -3(7)  
          C(23)-C(18)-C(19)-C(20)                               2.2(18)  
          C(17)-C(18)-C(19)-C(20)                             179.8(10)  
          C(23B)-C(18B)-C(19B)-C(20B)                          -1(3)  
          C(17)-C(18B)-C(19B)-C(20B)                         -179.2(16)  
          C(18)-C(19)-C(20)-C(21)                              -0.3(11)  
          C(18B)-C(19B)-C(20B)-C(21B)                           2(2)  
          C(19)-C(20)-C(21)-C(22)                              -1.7(11)  
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          C(19B)-C(20B)-C(21B)-C(22B)                          -1.7(18)  
          C(20)-C(21)-C(22)-C(23)                               1.6(12)  
          C(20B)-C(21B)-C(22B)-C(23B)                           0.2(16)  
          C(19)-C(18)-C(23)-C(22)                              -2(2)  
          C(17)-C(18)-C(23)-C(22)                            -179.8(11)  
          C(21)-C(22)-C(23)-C(18)                               0.3(15)  
          C(19B)-C(18B)-C(23B)-C(22B)                           0(3)  
          C(17)-C(18B)-C(23B)-C(22B)                          177.8(14)  
          C(21B)-C(22B)-C(23B)-C(18B)                           1(2)  
          O(27)-C(24)-C(25)-O(29)                             153.84(14)  
          O(26)-C(24)-C(25)-O(29)                             -26.0(2)  
          O(27)-C(24)-C(25)-O(28)                             -25.46(18)  
          O(26)-C(24)-C(25)-O(28)                             154.67(12)  
         ________________________________________________________________  
   
 
   
 Table 2.7.  Hydrogen bonds for Mlt45 [Å and deg.].  
 ____________________________________________________________________________  
   
 D-H...A                      d(D-H)      d(H...A)    d(D...A)    <(DHA)  
 
N8-H8...O27                    0.923       2.026       2.894      155.98     
N8-H8...O28                    0.923       2.335       2.998      128.54      
O26-H26...O26[-x+2,-y+1,-z+1 ] 1.244       1.244       2.488      180.00     
O28-H28...O28[-x+2,-y,-z+1 ]   1.236       1.236       2.471      179.97     
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